<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Transl Int Med</journal-id><journal-id journal-id-type="iso-abbrev">J Transl Int Med</journal-id><journal-id journal-id-type="publisher-id">jtim</journal-id><journal-id journal-id-type="doi">jtim</journal-id><journal-title-group><journal-title>Journal of Translational Internal Medicine</journal-title></journal-title-group><issn pub-type="ppub">2450-131X</issn><issn pub-type="epub">2224-4018</issn><publisher><publisher-name>De Gruyter</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC10732499</article-id><article-id pub-id-type="publisher-id">jtim-2023-0124</article-id><article-id pub-id-type="doi">10.2478/jtim-2023-0124</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Exosomes and their derivatives as biomarkers and therapeutic delivery agents for cardiovascular diseases: Situations and challenges</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Yunyang</given-names></name><xref rid="j_jtim-2023-0124_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Wan</surname><given-names>Weimin</given-names></name><xref rid="j_jtim-2023-0124_aff_002" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Zeng</surname><given-names>Huixuan</given-names></name><xref rid="j_jtim-2023-0124_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Xiang</surname><given-names>Ze</given-names></name><xref rid="j_jtim-2023-0124_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Mo</given-names></name><xref rid="j_jtim-2023-0124_aff_002" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Yao</surname><given-names>Yiwen</given-names></name><xref rid="j_jtim-2023-0124_aff_003" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yuan</given-names></name><xref rid="j_jtim-2023-0124_aff_004" ref-type="aff"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0574-7456</contrib-id><name><surname>Bortolanza</surname><given-names>Mariza</given-names></name><email xlink:href="mailto:mariza.bortolanza@uks.eu">mariza.bortolanza@uks.eu</email><xref rid="j_jtim-2023-0124_aff_003" ref-type="aff"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0087-3744</contrib-id><name><surname>Wu</surname><given-names>Jian</given-names></name><email xlink:href="mailto:wujianglinxing@163.com">wujianglinxing@163.com</email><xref rid="j_jtim-2023-0124_aff_002" ref-type="aff"/></contrib><aff id="j_jtim-2023-0124_aff_001"><institution>Zhejiang University School of Medicine</institution>, <city>Hangzhou</city> 310009, <addr-line>Zhejiang Province</addr-line>, <country country="CN">China</country></aff><aff id="j_jtim-2023-0124_aff_002"><institution>Department of Clinical Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University</institution>, <city>Suzhou</city>
<postal-code>215008</postal-code>, <addr-line>Jiangsu Province</addr-line>, <country country="CN">China</country></aff><aff id="j_jtim-2023-0124_aff_003"><institution>Department of Internal Medicine V-Pulmonology, Allergology, Respiratory Intensive Care Medicine, Saarland University Hospital</institution>, <postal-code>66424</postal-code>
<city>Homburg</city>, <country country="DE">Germany</country></aff><aff id="j_jtim-2023-0124_aff_004"><institution>Department of Cardiology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University</institution>, <city>Suzhou</city>
<postal-code>215008</postal-code>, <addr-line>Jiangsu Province</addr-line>, <country country="CN">China</country></aff></contrib-group><author-notes><p># These authors contributed equally to this work.</p><corresp> Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, 242 Guangji Road, Suzhou 215008, Jiangsu Province, China, Department of Internal Medicine V-Pulmonology, Allergology, Respiratory Intensive Care Medicine, Saarland University Hospital, 66424 Homburg, Germany</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>20</day><month>12</month><year>2023</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>12</month><year>2023</year></pub-date><volume>11</volume><issue>4</issue><fpage>341</fpage><lpage>354</lpage><permissions><copyright-statement>&#x000a9; 2023 Yunyang Xu, Weimin Wan, Huixuan Zeng, Ze Xiang, Mo Li, Yiwen Yao,
Yuan Li, Mariza Bortolanza, Jian Wu, published by De Gruyter on behalf of Scholar Media Publishing</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Yunyang Xu, Weimin Wan, Huixuan Zeng, Ze Xiang, Mo Li, Yiwen Yao,
Yuan Li, Mariza Bortolanza, Jian Wu, published by De Gruyter on behalf of Scholar Media Publishing</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under the Creative Commons Attribution 4.0 International License.</license-p></license></permissions><abstract><title>Abstract</title><p>Microvesicles known as exosomes have a diameter of 40 to 160 nm and are derived from small endosomal membranes. Exosomes have attracted increasing attention over the past ten years in part because they are functional vehicles that can deliver a variety of lipids, proteins, and nucleic acids to the target cells they encounter. Because of this function, exosomes may be used for the diagnosis, prognosis and treatment of many diseases. All throughout the world, cardiovascular diseases (CVDs) continue to be a significant cause of death. Because exosomes are mediators of communication between cells, which contribute to many physiological and pathological aspects, they may aid in improving CVD therapies as biomarkers for diagnosing and predicting CVDs. Many studies demonstrated that exosomes are associated with CVDs, such as coronary artery disease, heart failure, cardiomyopathy and atrial fibrillation. Exosomes participate in the progression or inhibition of these diseases mainly through the contents they deliver. However, the application of exosomes in diferent CVDs is not very mature. So further research is needed in this field.</p></abstract><kwd-group><title>Key words</title><kwd>cardiovascular disease</kwd><kwd>exosome</kwd><kwd>miRNA</kwd><kwd>diagnosis</kwd><kwd>prognosis</kwd></kwd-group><funding-group><funding-statement>This work was financially supported by the National Key R&#x00026;D Program of China (No.2022YFE0209900), the National Natural Science Foundation of China (No.82272396) and Suzhou Medical and Health Science and Technology Innovation Project (No.SKY2022057).
</funding-statement></funding-group><counts><page-count count="14"/></counts></article-meta></front><body><sec id="j_jtim-2023-0124_s_001"><title>Introduction</title><p>All cells and most organisms produce physiologically functional extracellular vesicles (EVs). The classification of EVs is constantly changing, but they can generally be categorized into exosomes and ectosomes.<sup>[<xref rid="j_jtim-2023-0124_ref_001" ref-type="bibr">1</xref>, <xref rid="j_jtim-2023-0124_ref_002" ref-type="bibr">2</xref>, <xref rid="j_jtim-2023-0124_ref_003" ref-type="bibr">3</xref>]</sup> Ectosomes are vesicles produced directly from the plasma membrane to the outgoing bud, which produces microvesicles, microparticles, and large vesicles diameters of 50 nm to 1 &#x003bc;m.<sup>[<xref rid="j_jtim-2023-0124_ref_001" ref-type="bibr">1</xref>]</sup> In contrast, exosomes are small endosomederived membrane microvesicles with diameters of 40 to 160 nm.<sup>[<xref rid="j_jtim-2023-0124_ref_001" ref-type="bibr">1</xref>,<xref rid="j_jtim-2023-0124_ref_004" ref-type="bibr">4</xref>]</sup> Over the past decade, increasing attention has been given to exosomes, partly because they are functional vehicles that carry a variety of lipids, proteins and nucleic acids <sup>[<xref rid="j_jtim-2023-0124_ref_005" ref-type="bibr">5</xref>, <xref rid="j_jtim-2023-0124_ref_006" ref-type="bibr">6</xref>, <xref rid="j_jtim-2023-0124_ref_007" ref-type="bibr">7</xref>, <xref rid="j_jtim-2023-0124_ref_008" ref-type="bibr">8</xref>]</sup> to deliver to the surrounding cells. Moreover, there are also many important molecules on the exosomal membrane, such as tetraspanins (CD9, CD63, etc.), intracellular adhesion molecules (ICAMs), major histocompatibility complex (MHC) class I, MHC class II, integrins and different kinds of receptors, which play significant roles <sup>[<xref rid="j_jtim-2023-0124_ref_004" ref-type="bibr">4</xref>,<xref rid="j_jtim-2023-0124_ref_009" ref-type="bibr">9</xref>]</sup> by modifying target cells&#x02019; physiological functions. For instance, exosomes can establish intercellular communication by delivering cargo to recipient cells, which is essential for various cellular functions, including immune response, signal transduction, and antigen presentation.<sup>[<xref rid="j_jtim-2023-0124_ref_010" ref-type="bibr">10</xref>-<xref rid="j_jtim-2023-0124_ref_012" ref-type="bibr">12</xref>]</sup> Furthermore, exosomes have enormous therapeutic potential for several of conditions, including chronic inflammation, lipid metabolism disorders, and cardiovascular disease, owing to their ability to transport biological material.<sup>[<xref rid="j_jtim-2023-0124_ref_013" ref-type="bibr">13</xref>-<xref rid="j_jtim-2023-0124_ref_015" ref-type="bibr">15</xref>]</sup> Exosomes may also participate in numerous pathological processes in addition to their beneficial physiological roles. Certain exosome-borne microRNAs (miRNAs) are responsible for different cardiac diseases, such as stroke and hypertension.<sup>[<xref rid="j_jtim-2023-0124_ref_016" ref-type="bibr">16</xref>-<xref rid="j_jtim-2023-0124_ref_018" ref-type="bibr">18</xref>]</sup></p><p>Cardiovascular diseases (CVDs), including hypertension, heart failure (HF), atherosclerosis, stroke, ischemic heart diseases, etc., continue to be a significant cause of death worldwide.<sup>[<xref rid="j_jtim-2023-0124_ref_014" ref-type="bibr">14</xref>,<xref rid="j_jtim-2023-0124_ref_019" ref-type="bibr">19</xref>,<xref rid="j_jtim-2023-0124_ref_020" ref-type="bibr">20</xref>]</sup> It is predicted that the increasing incidence of CVDs will lead to more than 23.6 million deaths by 2030 globally.<sup>[<xref rid="j_jtim-2023-0124_ref_021" ref-type="bibr">21</xref>,<xref rid="j_jtim-2023-0124_ref_022" ref-type="bibr">22</xref>]</sup> Atherosclerosis is the major cause of CVD, and its physiopathology also includes the remodeling of blood vessels, which may cause blood flow restrictions and influence the cardiovascular system.<sup>[<xref rid="j_jtim-2023-0124_ref_023" ref-type="bibr">23</xref>]</sup> Numerous risk factors for CVD have been identified, such as diabetes, cigarette smoking, obesity, sedentary behavior, and unhealthy lifestyles. Moreover, genetic factors and aging are also significant risk factors that increases CVD prevalence.<sup>[<xref rid="j_jtim-2023-0124_ref_024" ref-type="bibr">24</xref>]</sup> Studies have shown that CVDs are more common in patients with coronavirus illness 2019, who are at a higher risk of mortality.<sup>[<xref rid="j_jtim-2023-0124_ref_025" ref-type="bibr">25</xref>-<xref rid="j_jtim-2023-0124_ref_027" ref-type="bibr">27</xref>]</sup> In summary, improving the rate of CVD recovery is critical.</p><p>Since exosomes are mediators of cell-to-cell communication, which are involved in several physiological and pathological processes and have the potential to function as biomarkers in clinical practice, they can play an integral role in improving CVD treatment.<sup>[<xref rid="j_jtim-2023-0124_ref_028" ref-type="bibr">28</xref>]</sup> In particular, the possible application of exosomes as messengers or regenerative tools in CVDs has been actively investigated.<sup>[<xref rid="j_jtim-2023-0124_ref_029" ref-type="bibr">29</xref>,<xref rid="j_jtim-2023-0124_ref_030" ref-type="bibr">30</xref>]</sup> In this review, we will introduce exosomes and their derivatives and discuss their existing and potential application in the diagnosis, prognosis and treatment of CVDs.</p></sec><sec id="j_jtim-2023-0124_s_002"><title>Exosomes and their derivatives</title><p>Following the combination of late endosomes/multivesicular bodies (MVBs) with the plasma membrane, some vesicles are delivered to the outside of cells, and are referred to as exosomes, which were first detected in 1983.<sup>[<xref rid="j_jtim-2023-0124_ref_031" ref-type="bibr">31</xref>]</sup> In 1985, this process was observed again in sheep.<sup>[<xref rid="j_jtim-2023-0124_ref_032" ref-type="bibr">32</xref>]</sup> In 1987, Rose Johnstone chose the term &#x0201c;exosome&#x0201d; to nominate these vesicles.<sup>[<xref rid="j_jtim-2023-0124_ref_033" ref-type="bibr">33</xref>]</sup> Initially, exosomes were viewed as waste products of damaged cells or byproducts without a function. Only in recent years has it been discovered that exosomes play an essential role in intercellular communication and many other cellular processes. Based on whether or not they have been artificially modified, exosomes can be divided into natural exosomes and engineered exosomes.<sup>[<xref rid="j_jtim-2023-0124_ref_034" ref-type="bibr">34</xref>]</sup></p><sec id="j_jtim-2023-0124_s_002_s_001"><title>Exosome biogenesis</title><p>Three processes are involved in exosome biogenesis: the formation of early endosomes, growth of MVBs, and release of exosomes.<sup>[<xref rid="j_jtim-2023-0124_ref_035" ref-type="bibr">35</xref>]</sup> The endosomes are formed after the invagination of the cell membrane followed by the accumulation of bioactive substances like proteins and miRNAs in the early sorting endosomes. Early endosomes then mature into late sorting endosomes (LSEs) with the participation of proteins such as the endocytosis sorting complex. After a second indentation, LSEs transform into MVBs. Eventually, MVBs fuse with the cell membrane and then the substances within MVBs are released from the cells in the form of vesicles, which are exosomes. The mechanisms for the formation of exosomes are diversified. One of the most well-known mechanisms is that this process depends on the endosomal sorting complexes required for transport (ESCRT) complexes.<sup>[<xref rid="j_jtim-2023-0124_ref_036" ref-type="bibr">36</xref>,<xref rid="j_jtim-2023-0124_ref_037" ref-type="bibr">37</xref>]</sup> ESCRT combines with successive complexes on the MVB membranes and sorts cargos that are ultimately secreted as exosomes.<sup>[<xref rid="j_jtim-2023-0124_ref_001" ref-type="bibr">1</xref>,<xref rid="j_jtim-2023-0124_ref_038" ref-type="bibr">38</xref>]</sup> In addition to this ESCRT-dependent mechanism, there are some ESCRT-independent mechanisms as well. For example, a mechanism associated with ceramides has been proposed, which is independent of ESCRT. The delivery of proteolipid protein into exosomes depends on the sphingolipid ceramide, and ESCRT is not involved in this process.<sup>[<xref rid="j_jtim-2023-0124_ref_039" ref-type="bibr">39</xref>]</sup> Moreover, substances like four-transmembrane domain proteins and lipid rafts participate in the formation of some exosomes as well.<sup>[<xref rid="j_jtim-2023-0124_ref_040" ref-type="bibr">40</xref>,<xref rid="j_jtim-2023-0124_ref_041" ref-type="bibr">41</xref>]</sup> In summary, exosome formation is complicated. The exact mechanism remains controversial and requires further research.</p><p>At the end of the formation process, exosomes detach from the plasma membrane and prepare for secretion, which can be categorized into autocrine, paracrine, and endocrine.<sup>[<xref rid="j_jtim-2023-0124_ref_042" ref-type="bibr">42</xref>]</sup> The secretion of exosomes is also a complicated process, regulated by many factors. Exosome release involves being shed from the membrane; additionally, actin and myosin interaction and an ATP-dependent contraction are also indispensable.<sup>[<xref rid="j_jtim-2023-0124_ref_043" ref-type="bibr">43</xref>]</sup> Many kinds of stimuli such as stress can also induce the secretion of exosomes.<sup>[<xref rid="j_jtim-2023-0124_ref_044" ref-type="bibr">44</xref>]</sup> Moreover, exosome release can be governed by Rab-related proteins (Rabs) as well. Rab5 and Rab7 are essential for the delivery of cargo to early endosomes.<sup>[<xref rid="j_jtim-2023-0124_ref_045" ref-type="bibr">45</xref>]</sup> Some other Rabs, such as Rab11 and Rab35, can also regulate exosome secretion.<sup>[<xref rid="j_jtim-2023-0124_ref_042" ref-type="bibr">42</xref>]</sup> Additionally, soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs), which promote vesicle fusion with the target membrane, can also regulate the secretion of exosomes.<sup>[<xref rid="j_jtim-2023-0124_ref_046" ref-type="bibr">46</xref>]</sup> Bonifacino <italic toggle="yes">et al</italic>. have found that SNARE protein vesicle-associated membrane protein 7 (VAMP7) is essential for exosome delivery in leukemic cells.<sup>[<xref rid="j_jtim-2023-0124_ref_047" ref-type="bibr">47</xref>]</sup> Another SNARE protein, YKT6, also regulates exosome release. Exosomal proteins, tumor susceptibility gene 101 protein (TSG101), WNT3A and vacuolar protein sorting-associated protein (VPS)26/35 released by human embryonic kidney HEK293 cells were reduced by YKT6 depletion, according to a study.<sup>[<xref rid="j_jtim-2023-0124_ref_048" ref-type="bibr">48</xref>]</sup></p><fig position="float" id="j_jtim-2023-0124_fig_001" fig-type="figure"><label>Figure 1</label><caption><p>The biogenesis and delivery of exosomes.</p></caption><graphic xlink:href="j_jtim-2023-0124_fig_001" position="float"/></fig></sec><sec id="j_jtim-2023-0124_s_002_s_002"><title>Physiological functions</title><p>Once exosomes exit the cells, they begin to carry out their physiological functions. Once released, exosomes fuse with recipient cells&#x02019; plasma membranes, releasing their contents.<sup>[<xref rid="j_jtim-2023-0124_ref_049" ref-type="bibr">49</xref>]</sup> Surface proteins on some exosomes can bind to recipient cells&#x02019; surface receptors and induce intracellular signaling.<sup>[<xref rid="j_jtim-2023-0124_ref_050" ref-type="bibr">50</xref>,<xref rid="j_jtim-2023-0124_ref_051" ref-type="bibr">51</xref>]</sup> After being absorbed, exosomal content can generate several physiological or pathological responses in recipient cells, one of the most critical functions being to induce an immune response. In dendritic cells (DCs), exosomes can deliver MHC class I and II molecules and then activate immune cells, such as CD8<sup>+</sup> and CD4<sup>+</sup> T-cells.<sup>[<xref rid="j_jtim-2023-0124_ref_052" ref-type="bibr">52</xref>]</sup> Regardless of maturity, exosomes released by human DCs can promote a T helper 1 response.<sup>[<xref rid="j_jtim-2023-0124_ref_053" ref-type="bibr">53</xref>]</sup> During bacterial infection, antibacterial immune responses can also be boosted by exosomes that promote the presentation of macrophage-derived bacterial antigens.<sup>[<xref rid="j_jtim-2023-0124_ref_054" ref-type="bibr">54</xref>]</sup> Other physiological functions regulated by exosomes, such as stem cell maintenance and tissue repair, are all of great importance to the body.<sup>[<xref rid="j_jtim-2023-0124_ref_055" ref-type="bibr">55</xref>,<xref rid="j_jtim-2023-0124_ref_056" ref-type="bibr">56</xref>]</sup></p></sec><sec id="j_jtim-2023-0124_s_002_s_003"><title>Pathological functions</title><p>Besides biological functions, exosomes also have many pathological functions, for exosomes are involved in many diseases.<sup>[<xref rid="j_jtim-2023-0124_ref_057" ref-type="bibr">57</xref>, <xref rid="j_jtim-2023-0124_ref_058" ref-type="bibr">58</xref>, <xref rid="j_jtim-2023-0124_ref_059" ref-type="bibr">59</xref>]</sup> As an example of neurodegenerative diseases, some studies have revealed that several proteins associated with neurodegenerative diseases are transported in exosomes. In patients with Parkinson&#x02019;s disease (PD), Alzheimer&#x02019;s disease (AD) and undrafted amyotrophic lateral sclerosis (ALS), exosomes containing aggregation-prone proteins were discovered.<sup>[<xref rid="j_jtim-2023-0124_ref_060" ref-type="bibr">60</xref>-<xref rid="j_jtim-2023-0124_ref_062" ref-type="bibr">62</xref>]</sup> Exosomes are also involved in cancer. Several studies have previously reported that oncogenic proteins and nucleic acids can be delivered via exosomes into cancer cells, which can alter the activity of recipient cells and play a critical role in many physiological processes. Proteins, mRNAs and miRNAs from prostate cancer cell-derived exosomes can induce the neoplastic transformation of adipose-derived stem cells (ASCs). Additionally, other tumor-derived exosomes may boost tumor thrombosis and angiogenesis by activating endothelial cells.<sup>[<xref rid="j_jtim-2023-0124_ref_050" ref-type="bibr">50</xref>,<xref rid="j_jtim-2023-0124_ref_063" ref-type="bibr">63</xref>]</sup> In CVDs, exosomes can play a significant role as well, including peripartum cardiomyopathy and sepsis-induced cardiomyopathy. Some researchers recently demonstrated that exosomes released by cardiac fibroblasts, which are enriched in miRNAs, can induce cardiomyocyte hypertrophy. This process is regulated by silencing sarcoplasmic protein sorbin, SH3 domain-containing protein 2 (SORBS2), PDZ and LIM domain 5 (PDLIM5) proteins<sup>[<xref rid="j_jtim-2023-0124_ref_064" ref-type="bibr">64</xref>]</sup> (<xref rid="j_jtim-2023-0124_fig_001" ref-type="fig">Figure 1</xref>).</p><p>Due to exosomes&#x02019; pathological or physiological functions, they can be applied in the diagnosis, prognosis, and treatment of numerous diseases. As exosomes contain many bioactive substances and can interact with their recipient cells, they may function as an appealing marker and treatment strategy in cancer and other pathologies. Besides, exosomes can carry medicinal drugs for corresponding diseases so that they are capable of delivering drugs with high drug-loading capacity and accuracy and poor immunogenicity. There is no doubt that exosomes can be a promising tool and provide new therapeutic approaches for many diseases,<sup>[<xref rid="j_jtim-2023-0124_ref_065" ref-type="bibr">65</xref>-<xref rid="j_jtim-2023-0124_ref_067" ref-type="bibr">67</xref>]</sup> but further research is still required until they can be widely used in clinical practice.</p></sec></sec><sec id="j_jtim-2023-0124_s_003"><title>Exosomes and their derivatives in different cardiovascular diseases</title><p>As mentioned earlier, CVDs constitute the most common cause of death. The types and genetic diversity of CVDs, as well as the side effects of traditional gene therapy, make non-targeted therapies unsuitable for CVDs.<sup>[<xref rid="j_jtim-2023-0124_ref_068" ref-type="bibr">68</xref>]</sup> Thus, there is a need to develop disease-specific therapies, such as the use of delivery vehicles with specific therapeutic targets. Exosomes may be a promising treatment strategy for CVDs.<sup>[<xref rid="j_jtim-2023-0124_ref_069" ref-type="bibr">69</xref>-<xref rid="j_jtim-2023-0124_ref_072" ref-type="bibr">72</xref>]</sup> As a deliverer of the signaling molecules, exosome-regulated communication between different cells of the heart has been shown to play a crucial role in the progression of cardiac diseases and the maintenance of cardiac homeostasis.<sup>[<xref rid="j_jtim-2023-0124_ref_073" ref-type="bibr">73</xref>]</sup> Here, we introduce the application of exosomes in a few different kinds of CVDs.</p><sec id="j_jtim-2023-0124_s_003_s_001"><title>Coronary artery diseases</title><p>Coronary artery disease (CAD), a kind of cardiovascular disease that is caused by atherosclerosis or occlusion of the coronary arteries, has been one of the major public health threats worldwide, especially in middle-aged and older individuals.<sup>[<xref rid="j_jtim-2023-0124_ref_074" ref-type="bibr">74</xref>]</sup> The various clinical manifestations of CAD include myocardial infarction, stable and unstable angina, and sudden cardiac death.<sup>[<xref rid="j_jtim-2023-0124_ref_075" ref-type="bibr">75</xref>]</sup> Furthermore, CAD can be divided into two categories, acute coronary syndrome (ACS) and stable CAD (SCAD), according to different clinical characteristics and therapeutic principles.</p><p>Because of exosomes&#x02019; essential roles in intercellular communication through the transfer of cargo, they can participate in the diagnosis, prognosis and treatment of CADs (<xref rid="j_jtim-2023-0124_tab_001" ref-type="table">Table 1</xref>). Especially the various RNAs wrapped in exosomes play very significant roles. Long noncoding RNAs (lncRNAs), which are more than 200 nucleotides in length, play a significant regulatory role in several diseases&#x02019; pathological processes.<sup>[<xref rid="j_jtim-2023-0124_ref_076" ref-type="bibr">76</xref>]</sup> Studies have shown that some lncRNAs in exosomes are essential in the pathogenesis of CAD. In addition, lncRNAs may function as biomarkers and be a part of specific therapeutic strategies for CAD.<sup>[<xref rid="j_jtim-2023-0124_ref_077" ref-type="bibr">77</xref>,<xref rid="j_jtim-2023-0124_ref_078" ref-type="bibr">78</xref>]</sup> For example, the death of macrophages and vascular endothelial cells in atherosclerosis is regulated by exosomal lncRNA growth arrest-specific 5 (GAS5).<sup>[<xref rid="j_jtim-2023-0124_ref_079" ref-type="bibr">79</xref>]</sup> In another study, quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) and microarray analysis verified the downregulation of SOCS2-AS1in patients with CADs. Since there is a clear link between exosomal SOCS2-AS1 and CAD morbidity, Liang <italic toggle="yes">et al</italic>. suggested that plasma exosome-derived SOCS2-AS1 may be a CAD indicator.<sup>[<xref rid="j_jtim-2023-0124_ref_080" ref-type="bibr">80</xref>]</sup></p><table-wrap position="float" id="j_jtim-2023-0124_tab_001"><label>Table 1</label><caption><p>The application of exosomal contents in CAD</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Exosomal content</th><th align="left" rowspan="1" colspan="1">Role</th><th align="left" rowspan="1" colspan="1">Mechanism</th><th align="left" rowspan="1" colspan="1">Type of study</th><th align="left" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">lncRNA GAS5</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Regulate vascular the endothelial apoptosis cells of macrophages and</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vitro</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_079" ref-type="bibr">79</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">lncRNA SOCS2-AS1</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Be downregulated in plasma from CAD patients</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_080" ref-type="bibr">80</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-126</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Be increased in patients with ACS</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_081" ref-type="bibr">81</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-21</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Be downregulated in patients with ACS</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_081" ref-type="bibr">81</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">PTEN</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Be increased in patients with ACS</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_081" ref-type="bibr">81</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-208a</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Be increased in patients with ACS</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_082" ref-type="bibr">82</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-146a</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Be with increased inflammatory in patients response with ACS and associated</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_083" ref-type="bibr">83</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Cyr61</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Be vascular increased remodeling in patients with ACS and regulate</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_084" ref-type="bibr">84</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-942-5p</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Be increased in patients with SCAD and regulate VEGFA&#x02013;VEGFR2, PI3K and MAPK signaling pathways</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_089" ref-type="bibr">89</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-149-5p</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Be increased in patients with SCAD and regulate VEGFA&#x02013;VEGFR2, PI3K and MAPK signaling pathways</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_089" ref-type="bibr">89</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-32-5p</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Be increased in patients with SCAD and regulate VEGFA&#x02013;VEGFR2, PI3K and MAPK signaling pathways</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_089" ref-type="bibr">89</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-19</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Inhibit OS by downregulating the expression of PTEN and BIM and activate the Akt and ERK signaling pathways</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vitro</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_096" ref-type="bibr">96</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-210</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Increase by stimulating cardiac the progenitor PI3K/Akt cells&#x02019; pathway tolerance to OS</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vitro</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_098" ref-type="bibr">98</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-133a</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Improve ejection cardiac fraction function and fractional through shortening left ventricular</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vitro</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_100" ref-type="bibr">100</xref>]</td></tr></tbody></table></table-wrap><p>ACS, one of the most common types of CADs, is a severe disease, which can be divided into unstable angina pectoris and acute myocardial infarction (AMI). Traditionally, clinically abnormal levels of certain cardiac biomarkers have been used to identify these diseases. Nowadays, some novel exosomal biomarkers have been identified for ACS diagnosis. Ling <italic toggle="yes">et al</italic>.<sup>[81]</sup> demonstrated that the levels of miR-126, miR-21, and phosphatase and tensin homolog (PTEN) in serum exosomes were distinctly different in patients with ACS and healthy individuals. According to the study, the expression levels of miR-21 were down-regulated in the patients, whereas those of miR-126 and PTEN levels were higher. The results showed that miR-21, miR-126 and PTEN may serve as specific serum markers for ACS. Another miRNA, miR-208a, is also associated with ACS. Bi <italic toggle="yes">et al</italic>. detected that the exosomal miR-208a levels in patients with ACS were up-regulated, indicating the diagnostic and prognostic function of exosomal miR-208a for ACS.<sup>[<xref rid="j_jtim-2023-0124_ref_082" ref-type="bibr">82</xref>]</sup> Furthermore, Li <italic toggle="yes">et al</italic>. found significantly increased levels of serum exosomal miR-146a in patients with ACS than in the control group, suggesting that it may be a novel diagnostic biomarker for such patients. The relationship between miR-146a and inflammatory response was also demonstrated in this study.<sup>[<xref rid="j_jtim-2023-0124_ref_083" ref-type="bibr">83</xref>]</sup> Additionally, some exosomal proteins may be involved in the diagnosis and prognosis of ASC. Li <italic toggle="yes">et al</italic>. confirmed increased expression levels of exosome&#x02011;derived cysteine&#x02011;rich protein 61 (Cyr61) in the plasma and linked it to ASC in their study. This indicates that exosomal Cyr61 has the potential to be used in the diagnosis and prognosis of ACS. Moreover, Cyr61 can serve a regulatory role in vascular remodeling <italic toggle="yes">in vitro</italic>.<sup>[<xref rid="j_jtim-2023-0124_ref_084" ref-type="bibr">84</xref>]</sup></p><p>When it comes to SCAD, exosomal miRNAs may also function as biomarkers. In a study, three circulating exosomal miRNAs, miR-942-5p, miR-149-5p, and miR-32-5p, were significantly increased in patients with SCAD, and atherosclerosis was the most significant pathological basis of CAD. Atherosclerosis is associated with important signaling pathways, such as the vascular endothelial growth factor A-vascular endothelial growth factor receptor 2 (VEGFA-VEGFR2) signaling pathway. These signaling pathways can generate diverse responses in the development of atherosclerosis as well as participate in the regulation of atherosclerosis.<sup>[<xref rid="j_jtim-2023-0124_ref_085" ref-type="bibr">85</xref>-<xref rid="j_jtim-2023-0124_ref_088" ref-type="bibr">88</xref>]</sup> Through the regulation of these signaling pathways, the aforementioned three miRNAs may play essential roles in SCAD morbidity. They may also function as novel diagnostic and prognostic indicators for patients with SCAD owing to their high expression in such patients.<sup>[<xref rid="j_jtim-2023-0124_ref_089" ref-type="bibr">89</xref>]</sup> Other than miRNAs, circular RNAs (circRNAs) are also abundant in exosomes, and may also function as prediction targets and biomarkers for CAD prognosis.<sup>[<xref rid="j_jtim-2023-0124_ref_090" ref-type="bibr">90</xref>,<xref rid="j_jtim-2023-0124_ref_091" ref-type="bibr">91</xref>]</sup></p><p>In addition to their significant roles in CAD prognosis and diagnosis, exosomes can also be used in treatment. The progression of CADs, particularly AMI, is significantly influenced by oxidative stress (OS).<sup>[<xref rid="j_jtim-2023-0124_ref_092" ref-type="bibr">92</xref>]</sup> Inequality between the antioxidant defense systems and the production of reactive oxygen species (ROS) is the leading cause of OS.<sup>[<xref rid="j_jtim-2023-0124_ref_093" ref-type="bibr">93</xref>,<xref rid="j_jtim-2023-0124_ref_094" ref-type="bibr">94</xref>]</sup> Some studies have found that exosomes can regulate OS in CADs, and miRNAs play an important role in this process. An important factor in ischemia-reperfusion injury is OS-induced apoptosis following myocardial ischemiareperfusion, which was substantially reduced when miR-19a was injected into the mouse myocardium.<sup>[<xref rid="j_jtim-2023-0124_ref_095" ref-type="bibr">95</xref>]</sup> The underlying mechanism involves miR-19a down-regulating the expression of PTEN and Bcl-2-like protein 11 (BIM) in cardiomyocytes and the activation of Akt and extracellular signal-regulated kinase (ERK) pathways.<sup>[<xref rid="j_jtim-2023-0124_ref_096" ref-type="bibr">96</xref>]</sup> Transcriptional factor hypoxia-inducible factor (HIF-1) is crucial in the cellular response to hypoxic environments.<sup>[<xref rid="j_jtim-2023-0124_ref_097" ref-type="bibr">97</xref>]</sup> Exosomal miR-210 can be up-regulated by HIF-1. Huang <italic toggle="yes">et al</italic>. found that the activation of the phosphoinositide 3-kinase (PI3K)/Akt pathway led to exosome-rich miR-210 in endothelial cells exposed to hypoxia and boost the cardiac progenitor cells&#x02019; tolerance to OS.<sup>[<xref rid="j_jtim-2023-0124_ref_098" ref-type="bibr">98</xref>]</sup> Therefore, exosomal miR-210 may also be used in the treatment of CADs. miR-133a is a kind of miRNA abundant in the heart and can promote this organ&#x02019;s growth and development.<sup>[<xref rid="j_jtim-2023-0124_ref_099" ref-type="bibr">99</xref>]</sup> In the myocardial infarction (MI) rat models, the decrease in left ventricular ejection fraction can improved cardiac function as a result of miR-133 overexpression;<sup>[<xref rid="j_jtim-2023-0124_ref_100" ref-type="bibr">100</xref>]</sup> thus, miR-133a is an MI biomarker.<sup>[<xref rid="j_jtim-2023-0124_ref_101" ref-type="bibr">101</xref>]</sup> Exosomes derived from mesenchymal stem cells (MSCs) play crucial roles in immune responses. Li <italic toggle="yes">et al</italic>. demonstrated that the miR-let7/high-mobility group AT-hook 2 (HMGA2)/nuclear factor-&#x003ba;B (NF-&#x003ba;B) pathway induced M2 macrophage polarization and regulated atherosclerosis in mice in an MSC-exosome study. Moreover, MSC-exosomes inhibited macrophage infiltration through the miR-let7/insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)/PTEN pathway. Based on the findings of this study, MSC-exosomes may be an effective strategy for preventing atherosclerosis as they may significantly reduce inflammation in atherosclerosis plaques.<sup>[<xref rid="j_jtim-2023-0124_ref_102" ref-type="bibr">102</xref>]</sup> Cochain <italic toggle="yes">et al</italic>. also studied the interaction between exosomes and macrophages. Numerous functional phenotypes of macrophages were found in atherosclerotic plaques, which responded to the microenvironment and played various roles in vascular inflammation and atherosclerosis.<sup>[<xref rid="j_jtim-2023-0124_ref_103" ref-type="bibr">103</xref>]</sup> According to the findings of the research, the communication between cardiomyocytes and macrophages by promoting exosome-mediated macrophage polarization is critical for the maintenance of cardiac homeostasis. Exosomes may thus be a potential novel therapeutic strategy for several CADs by modulating macrophage polarization profiles.<sup>[<xref rid="j_jtim-2023-0124_ref_104" ref-type="bibr">104</xref>]</sup></p></sec><sec id="j_jtim-2023-0124_s_003_s_002"><title>Heart failure</title><p>Many patients with CVDs experience HF, which is a multifaceted and challenging condition. HF can be divided into systolic HF with reduced ejection fraction (HFrEF) and diastolic HF with preserved ejection fraction (HFpEF). Owing to the high morbidity and death rate, HF is a significant healthcare burden worldwide.<sup>[<xref rid="j_jtim-2023-0124_ref_105" ref-type="bibr">105</xref>-<xref rid="j_jtim-2023-0124_ref_108" ref-type="bibr">108</xref>]</sup> Symptoms of HF include paroxysmal nocturnal dyspnea, orthopnea, and dyspnea. Furthermore, an insufficient heart rate can result in fatigue, weakness, and exercise intolerance. Because these symptoms are mainly nonspecific, it is difficult to distinguish patients with HF from those with other CVDs.<sup>[<xref rid="j_jtim-2023-0124_ref_109" ref-type="bibr">109</xref>]</sup> Hence, the clinical diagnosis of HF is challenging and the difficulties in the diagnosis may result in delayed therapy, which will eventually result in an incorrect prognosis. It is necessary to identify molecules closely related to the occurrence and development of HF, since they may promote early detection.</p><p>Exosomes may participate in the clinical diagnosis, prognosis, and treatment of HF and resolve the challenges in determining HF (<xref rid="j_jtim-2023-0124_tab_002" ref-type="table">Table 2</xref>). One of the most prevalent types of cardiomyopathies, dilated cardiomyopathy (DCM), is the primary cause of HF.<sup>[<xref rid="j_jtim-2023-0124_ref_110" ref-type="bibr">110</xref>]</sup> Acute HF (AHF) is a severe pathophysiological state of DCM. Wu <italic toggle="yes">et al</italic>. found that miR-92b-5p in serum exosomes was significantly up-regulated in patients with DCM-AHF. Additionally, it was demonstrated that exosomal miR-92b-5p was responsible for the progression of DCM-AHF owing to a positive connection between exosomal miR-92b-5p and cardiac chamber enlargement. Thus, serum exosomal miR-92b-5p is a valuable diagnostic and prognostic biomarker for DCM-AHF.<sup>[<xref rid="j_jtim-2023-0124_ref_111" ref-type="bibr">111</xref>]</sup> Peripartum cardiomyopathy (PCM) is a severe pregnancy-correlated cardiomyopathy in women, which can lead to PCM-HF. The symptom of this disease is an abrupt occurrence of HF in the late stage of pregnancy.<sup>[<xref rid="j_jtim-2023-0124_ref_112" ref-type="bibr">112</xref>]</sup> Damaged cardiomyocyte cells secrete miR-146a, which can be detected in serum exosomes and exosomes in circulation.<sup>[<xref rid="j_jtim-2023-0124_ref_113" ref-type="bibr">113</xref>]</sup> Compared to those with DCM-AHF and pregnancy-matched healthy controls, patients with PCM-AHF experience an increase in the plasma level of miR-146a.<sup>[<xref rid="j_jtim-2023-0124_ref_114" ref-type="bibr">114</xref>]</sup> Beg <italic toggle="yes">et al</italic>. also reported significantly higher levels of exosomal miR-146a in patients with HF than in healthy controls.<sup>[<xref rid="j_jtim-2023-0124_ref_113" ref-type="bibr">113</xref>]</sup> Therefore, exosomal miR-146a in exosomes can be developed as a specific diagnostic and prognostic biomarker for PCM-AHF.<sup>[<xref rid="j_jtim-2023-0124_ref_115" ref-type="bibr">115</xref>]</sup> Furthermore, exosomal miR-181c and miR-495 may be novel biomarkers for the pathogenesis of chronic HF (CHF).<sup>[<xref rid="j_jtim-2023-0124_ref_116" ref-type="bibr">116</xref>]</sup> Exosomes exclusively contain high levels of hsa_circ_0097435, a type of circular RNA. Han <italic toggle="yes">et al</italic>. performed the analysis of exosomes obtained from peripheral blood samples in patients with HF and healthy individuals and showed upregulated levels of hsa_circ_0097435 in patients with HF, and hsa_circ_0097435 was found to play an essential role in HF progression. Thus, hsa_circ_0097435 is a valuable biomarker for the clinical diagnosis and prognosis of HF.<sup>[<xref rid="j_jtim-2023-0124_ref_117" ref-type="bibr">117</xref>]</sup></p><table-wrap position="float" id="j_jtim-2023-0124_tab_002"><label>Table 2</label><caption><p>The application of exosomal contents in HF</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Exosomal content</th><th align="left" rowspan="1" colspan="1">Role</th><th align="left" rowspan="1" colspan="1">Mechanism</th><th align="left" rowspan="1" colspan="1">Type of study</th><th align="left" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">miR-92b-5p</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Be increased in patients with AHF</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_111" ref-type="bibr">111</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-146a</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Be specifically increased in patients with PCM-AHF</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_113" ref-type="bibr">113</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-181c</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Monitor the progression of CHF</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vitro</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_116" ref-type="bibr">116</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-495</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Monitor the progression of CHF</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vitro</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_116" ref-type="bibr">116</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">has_circ_0097435</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Promote HF occurrence and development</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_117" ref-type="bibr">117</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-30d-5p</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Be the downregulated cardioprotective in role patients of miR-with 30HF d in and HF reduce</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vivo</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_118" ref-type="bibr">118</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-126a-5p</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Be downregulated in patients with HF and decrease cardiac microvessel density and impair ventricular function</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_120" ref-type="bibr">120</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-214-3p</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">accelerate therapeutic the target progression of CHF and be used as</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vivo</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_122" ref-type="bibr">122</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">let-7i-5p</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Accelerate therapeutic the target progression of CHF and be used as</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vivo</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_122" ref-type="bibr">122</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">let-7g-5p</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Accelerate therapeutic the target progression of CHF and be used as</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vivo</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_122" ref-type="bibr">122</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-129-5p</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Protect necrosis the factor heart receptor from failure by targeting tumor</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vitro</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_123" ref-type="bibr">123</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-320a</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Promote myocardial fibroblast proliferation</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vitro</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_124" ref-type="bibr">124</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-1246</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Attenuated damage hypoxia-induced myocardial tissue</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vitro</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_125" ref-type="bibr">125</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="j_jtim-2023-0124_tab_005"><label>Table 5</label><caption><p>The application of exosomal contents in myocarditis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Exosomal content</th><th align="left" rowspan="1" colspan="1">Role</th><th align="left" rowspan="1" colspan="1">Mechanism</th><th align="left" rowspan="1" colspan="1">Type of study</th><th align="left" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">hsa-miR-146a-5p</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Has FM patients higher expression levels in exosomes of pediatric</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_151" ref-type="bibr">151</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">hsa-miR-23a-3p</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Has FM patients higher expression levels in exosomes of pediatric</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_151" ref-type="bibr">151</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">hsa-miR-27a-3p</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Has FM patients higher expression levels in exosomes of pediatric</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_151" ref-type="bibr">151</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">hsa-miR-155</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Be differently expressed in FM patients</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_152" ref-type="bibr">152</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">hsa-miR-320a</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Be differently expressed in FM patients</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_152" ref-type="bibr">152</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Anti-CVB3 vaccine</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Enhance resistance to CVB3-induced viral myocarditis</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vivo</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_154" ref-type="bibr">154</xref>]</td></tr></tbody></table></table-wrap><p>Exosomes are associated with the treatment of HF as well. Exosomal miR-30d-5p and miR-126a-5p have been associated with diabetic HFpEF. The levels of exosomal miR-30d, which is known to be cardioprotective, are decreased in HF.<sup>[<xref rid="j_jtim-2023-0124_ref_118" ref-type="bibr">118</xref>,<xref rid="j_jtim-2023-0124_ref_119" ref-type="bibr">119</xref>]</sup> Reduced level of miR-126a also contributes to HF by impairing ventricular function.<sup>[<xref rid="j_jtim-2023-0124_ref_120" ref-type="bibr">120</xref>]</sup> Huang <italic toggle="yes">et al</italic>. proposed that miR-30d and miR-126a may be valuable markers and therapeutic targets for HFpEF in patients with diabetes.<sup>[<xref rid="j_jtim-2023-0124_ref_121" ref-type="bibr">121</xref>]</sup> In another study, the researchers tested the effects of the three miRNAs, miR-214-3p, let-7i-5p, and let-7g-5p, on inflammation. These are circulating exosomal co-change miRNAs and can be found in the rostral ventrolateral medulla (RVLM) in patients with CHF. The results demonstrated that miR-214-3p worked as a pro-inflammatory mediator, whereas let-7g-5p and let-7i-5p inhibited inflammation. These three exosomal miRNAs, according to the research, may accelerate CHF progression by enhancing RVLM inflammation by facilitating communication between the periphery and center.<sup>[<xref rid="j_jtim-2023-0124_ref_122" ref-type="bibr">122</xref>]</sup> Therefore, these three co-change miRNAs in exosomes may be used as therapeutic targets for CHF in the future. Yan <italic toggle="yes">et al</italic>. suggested that exosomal miR-129-5p from MSC exosomes inhibited HF by targeting tumor necrosis factor receptor-associated factor 3 (TRAF3) and the subsequent NF-kB signaling. This regulatory axis can be used in the treatment of HF.<sup>[<xref rid="j_jtim-2023-0124_ref_123" ref-type="bibr">123</xref>]</sup> Another miRNA, miR-320a, was also associated with HF. Compared to healthy controls, serum exosomal miR&#x02011;320a and sST2 content were not only significantly increased in patients with CHF, but the levels also correlated with clinical CHF indices. miR-320a can promote myocardial fibroblast proliferation through the phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA)/Akt/mammalian target of rapamycin (mTOR) signaling pathway. As a result, exosomal miR&#x02011;320a may function as a specific target for therapeutic strategies for CHF.<sup>[<xref rid="j_jtim-2023-0124_ref_124" ref-type="bibr">124</xref>]</sup> Moreover, human umbilical cord mesenchymal stem cells (hucMSCs) release miR-1246 during CHF and serine protease 23 (PRSS23) is a specific target of miR-1246. Wang <italic toggle="yes">et al</italic>. found that exosomal miR-1246 from hucMSCs inhibited HF by targeting PRSS23. The possible underlying mechanism of miR- 1246-mediated reduction in myocardial tissue damage is by targeting PRSS23, which is followed by the inhibition of smooth muscle actin signaling. Therefore, miR-1246 may also be used for the treatment of HF.<sup>[<xref rid="j_jtim-2023-0124_ref_125" ref-type="bibr">125</xref>]</sup></p></sec><sec id="j_jtim-2023-0124_s_003_s_003"><title>Cardiomyopathy</title><p>Cardiomyopathy is a group of heterogeneous myocardial diseases. They can be caused by abnormalities in cardiac mechanical and electrical activities, which are manifested as inappropriate hypertrophy or expansion of the ventricle. Exosomes can participate in the diagnosis, prognosis and treatment of cardiomyopathy in many ways (<xref rid="j_jtim-2023-0124_tab_003" ref-type="table">Table 3</xref>).</p><table-wrap position="float" id="j_jtim-2023-0124_tab_003"><label>Table 3</label><caption><p>The application of exosomal contents in cardiomyopathy</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Exosomal content</th><th align="left" rowspan="1" colspan="1">Role</th><th align="left" rowspan="1" colspan="1">Mechanism</th><th align="left" rowspan="1" colspan="1">Type of study</th><th align="left" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">miR-1</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Be increased in patients with DCM</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In</italic> Human <italic toggle="yes">vivo</italic> study study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_127" ref-type="bibr">127</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-208</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Be increased in patients with DCM</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In</italic> Human <italic toggle="yes">vivo</italic> study study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_127" ref-type="bibr">127</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-499</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Be increased in patients with DCM</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In</italic> Human <italic toggle="yes">vivo</italic> study study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_127" ref-type="bibr">127</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-19b-3p</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Positively correlate with myocardial status</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vivo</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_128" ref-type="bibr">128</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-181b-5p</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Positively correlate with myocardial status</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vivo</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_128" ref-type="bibr">128</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-126</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Be increased in patients with DCM</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vivo</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_129" ref-type="bibr">129</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-320</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Be increased in patients with DCM</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vivo</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_129" ref-type="bibr">129</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-19a</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Preserve size cardiac contractile function and reduce infarct</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vitro</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_096" ref-type="bibr">96</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-29b</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Alleviate fibrosis and cardiomyocyte uncoupling in DCM</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vivo</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_130" ref-type="bibr">130</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-455</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Alleviate fibrosis and cardiomyocyte uncoupling in DCM</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vivo</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_130" ref-type="bibr">130</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-26a</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Prevent cardiomyopathy CKD-induced muscle wasting and attenuate</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vivo</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_133" ref-type="bibr">133</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-155</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Mediate downregulating cardiomyocyte FoxO3a pyroptosis protein expression in uremic hearts by</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vivo</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_134" ref-type="bibr">134</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-122</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Improve cardiac remodeling and metabolic profiles</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_136" ref-type="bibr">136</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-29a</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Regulate cardiac parameters in human subjects</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_137" ref-type="bibr">137</xref>]</td></tr></tbody></table></table-wrap><p>In 1972, Rubler first described diabetic cardiomyopathy (DCM) as cardiac structural abnormalities without many other traditional cardiovascular diseases.<sup>[<xref rid="j_jtim-2023-0124_ref_126" ref-type="bibr">126</xref>]</sup> Many exosomal miRNAs can participate in the diagnosis of DCM. Some myocardial miRNAs, including miR-1, miR-208, and miR-499, are abundant in circulating exosomes. The changes in their expression levels may have a significant impact on myocardial injury and the levels of their expression may be indicators of DCM.<sup>[<xref rid="j_jtim-2023-0124_ref_127" ref-type="bibr">127</xref>]</sup> During the progression of DCM, miR-19b-3p and miR-181b-5p positively correlate with myocardial status in circulating exosomes. Therefore, their expression levels may also be used for the diagnosis and prognosis of DCM.<sup>[<xref rid="j_jtim-2023-0124_ref_128" ref-type="bibr">128</xref>]</sup> Moreover, Wang <italic toggle="yes">et al</italic>. found both expressions of miR-126 and miR-320 were increased in patients with DCM. miR-320 can inhibit angiogenesis and promote the development of cardiac function, so it may also be used in the treatment of DCM.<sup>[<xref rid="j_jtim-2023-0124_ref_129" ref-type="bibr">129</xref>]</sup></p><p>In the clinical treatment of cardiomyopathy, exosomes may also count. Yu <italic toggle="yes">et al</italic>. demonstrated that exosomes derived from MSCs abundant in GATA4 improved cardiac function and decreased infarct size. Hence, these exosomes may be used for the treatment of DCM. The possible mechanism is the inhibition of PTEN directly increases Akt and ERK activation and up-regulates miR-19a levels.<sup>[<xref rid="j_jtim-2023-0124_ref_096" ref-type="bibr">96</xref>]</sup> In another study, Chaturvedi <italic toggle="yes">et al</italic>. confirmed that exercise brings up a down-regulation in the expression of the matrix metalloproteinase 9 (MMP9) by up-regulating the expression levels of miR-29b and miR-455 in exosomes from cardiomyocytes, thereby inhibiting fibrosis in DCM.<sup>[<xref rid="j_jtim-2023-0124_ref_130" ref-type="bibr">130</xref>]</sup> Chronic kidney disease (CKD) may cause some CVDs such as uremic cardiomyopathy (UCM) and CKD-related diseases.<sup>[<xref rid="j_jtim-2023-0124_ref_131" ref-type="bibr">131</xref>,<xref rid="j_jtim-2023-0124_ref_132" ref-type="bibr">132</xref>]</sup> Wang <italic toggle="yes">et al</italic>. demonstrated that the high expression level of miR-26a in muscle prevented muscle wasting and attenuated cardiomyopathy via exosome-mediated miR-26a delivery. Results of the study suggested that miR-26a could inhibit muscle wasting and UCM by increasing insulin sensitivity.<sup>[<xref rid="j_jtim-2023-0124_ref_133" ref-type="bibr">133</xref>]</sup> miR-155 was also associated with UCM in another study. It was found that exosomal miR-155 plays an important role in mediating cardiomyocyte pyroptosis in uremic hearts, and this function is associated with the down-regulation of FoxO3a protein expression. These findings may provide novel insight into UCM and provide a novel therapeutic target for the disease.<sup>[<xref rid="j_jtim-2023-0124_ref_134" ref-type="bibr">134</xref>]</sup> Obesity has emerged as a global epidemic in recent years and is intimately linked to an increasing morbidity of heart disease.<sup>[<xref rid="j_jtim-2023-0124_ref_135" ref-type="bibr">135</xref>]</sup> Exosomal miR-122 was found to regulate mitochondrial function and cardiac remodeling during obesity-related cardiomyopathy. Mechanistically, through direct binding to mitochondrial protein ADP-ribosylation factor-like 2 (Arl-2), miR-122 regulated mitochondrial function, as well as cardiac function. Moreover, the researchers found circulating expression levels of miR-122 were positively correlated to the increase of NT-proBNP and negatively correlated to the cardiac ejection fraction (EF), and these two indicators are essential in indicating cardiomyopathy. Besides, hepatic miR-122 blocking could promote cardiac remodeling and metabolic profiles in mice with obesity and primary cardiomyocytes. All these findings indicated that miR-122 in exosomes might be used to treat obesity-related cardiomyopathy.<sup>[<xref rid="j_jtim-2023-0124_ref_136" ref-type="bibr">136</xref>]</sup> Another exosomal miRNA, miR-29a, is also associated with obesity-related cardiomyopathy. Li <italic toggle="yes">et al</italic>. found there is a link between exosomal miR-29a and cardiac parameters in patients, and miR-29a sponge therapy can be used to combat obesity-mediated cardiac dysfunction. So, miR-29a may also play an important role in the clinical treatment of obesity-related cardiomyopathy.<sup>[<xref rid="j_jtim-2023-0124_ref_137" ref-type="bibr">137</xref>]</sup> Besides, cardiac stem cells (CSCs) can be used for the therapies for cardiomyopathies, but some limitations exist. Most of CSCs&#x02019; regenerative effects are attributed to CSC-derived exosomes (CSC-XOs).<sup>[<xref rid="j_jtim-2023-0124_ref_138" ref-type="bibr">138</xref>]</sup> In a study on CSC-XOs, Vandergriff <italic toggle="yes">et al</italic>. demonstrated that mice receiving CSC-XOs acquired superior cardiac function, as well as attenuated apoptosis and fibrosis. So, the application of CSC-XOs has the potential to overcome the limitations of existing therapies and develop cardiomyopathy treatment strategy.<sup>[<xref rid="j_jtim-2023-0124_ref_139" ref-type="bibr">139</xref>]</sup></p></sec><sec id="j_jtim-2023-0124_s_003_s_004"><title>Atrial fibrillation</title><p>Atrial fibrillation (AF) is the most prevalent one of heart arrhythmia and a significant worldwide burden.<sup>[<xref rid="j_jtim-2023-0124_ref_140" ref-type="bibr">140</xref>]</sup> The pathogenesis of this disease is associated with the patients&#x02019; age and many other factors.<sup>[<xref rid="j_jtim-2023-0124_ref_141" ref-type="bibr">141</xref>]</sup> Recent studies on AF have demonstrated the application of exosomes in the diagnosis, prognosis and treatment of AF (<xref rid="j_jtim-2023-0124_tab_004" ref-type="table">Table 4</xref>).</p><table-wrap position="float" id="j_jtim-2023-0124_tab_004"><label>Table 4</label><caption><p>The application of exosomal contents in AF</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Exosomal content</th><th align="left" rowspan="1" colspan="1">Role</th><th align="left" rowspan="1" colspan="1">Mechanism</th><th align="left" rowspan="1" colspan="1">Type of study</th><th align="left" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">miR-483-5p</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Be correlated with the AF</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_142" ref-type="bibr">142</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-142-5p</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Be correlated with the AF</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_142" ref-type="bibr">142</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-223-3p</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Be correlated with the AF</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_142" ref-type="bibr">142</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-382-3p</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Regulate the AF progression</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_143" ref-type="bibr">143</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-450a-2-3p</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Regulate the AF progression</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_143" ref-type="bibr">143</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-3126-5p</td><td align="left" rowspan="1" colspan="1">Diagnosis and prognosis</td><td align="left" rowspan="1" colspan="1">Regulate the AF progression</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_143" ref-type="bibr">143</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-146</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Inhibit EGR1 myocardial fibrosis by down-regulating the gene</td><td align="left" rowspan="1" colspan="1">Human study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_144" ref-type="bibr">144</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-17</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Inhibit TGF-&#x003b2;-induced fibrosis under oxidative stress</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vitro</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_145" ref-type="bibr">145</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-210</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Inhibit TGF-&#x003b2;-induced fibrosis under oxidative stress</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vitro</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_145" ref-type="bibr">145</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-320d</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Inhibit regulating cardiomyocyte STAT3 expression apoptosis in AF by negatively</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vivo</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_146" ref-type="bibr">146</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-150-5p</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Reduce the immune reactions and suppress the Th1 proliferation and secretion of the pro-inflammatory cytokines</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vitro</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_147" ref-type="bibr">147</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-142-3p</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Reduce the immune reactions and suppress the Th1 proliferation and secretion of the pro-inflammatory cytokines</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vitro</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_147" ref-type="bibr">147</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Let-7d</td><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Reduce the immune reactions and suppress the Th1 proliferation and secretion of the pro-inflammatory cytokines</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">In vitro</italic> study</td><td align="left" rowspan="1" colspan="1">[<xref rid="j_jtim-2023-0124_ref_147" ref-type="bibr">147</xref>]</td></tr></tbody></table></table-wrap><p>Many kinds of miRNAs in the exosomes can work as diagnostic biomarkers for AF. According to the research, the levels of miR-483-5p, miR-142-5p, and miR-223-3p were linked to AF, and further research demonstrated that the miR-483-5p was independently related to AF. Therefore these miRNAs may become specific diagnostic and prognostic biomarkers for AF.<sup>[<xref rid="j_jtim-2023-0124_ref_142" ref-type="bibr">142</xref>]</sup> In another study, Liu <italic toggle="yes">et al</italic>. found that the miR-382-3p, miR-450a-2-3p, and miR&#x02212;3126-5p in the exosomes are associated with AF, and especially the miR-382-3p seemed pivotal in the AF progression.<sup>[<xref rid="j_jtim-2023-0124_ref_143" ref-type="bibr">143</xref>]</sup></p><p>Exosomes can also be used as therapeutic approaches in the treatment of AF. The pathogenesis of the AF is mainly owed to fibrosis, remodeling, inflammation, and apoptosis in the heart. As exosomes can specifically regulate these processes, they can play significant roles in the clinical therapies for AF. miR-146 in exosomes from Adipose-derived stem cells (ADSCs) can inhibit myocardial fibrosis. Therefore, this kind of miRNA may be essential in treating AF. The mechanism is miR-146 could prevent myocardial fibrosis by inhibiting the expression of the gene EGR1.<sup>[<xref rid="j_jtim-2023-0124_ref_144" ref-type="bibr">144</xref>]</sup> Besides, exosomal miR-17 and miR-210 can also inhibit TGF- &#x003b2;-induced fibrosis.<sup>[<xref rid="j_jtim-2023-0124_ref_145" ref-type="bibr">145</xref>]</sup> The exosomal miR-320d from the ADSCs can indirectly inhibit cardiomyocyte apoptosis in AF by negatively regulating STAT3 expression, thus increasing survival. This method may provide novel treatment strategies for AF, thereby improving the clinical treatment of AF.<sup>[<xref rid="j_jtim-2023-0124_ref_146" ref-type="bibr">146</xref>]</sup> Furthermore, exosomes created from Tregs may transport the miR-150-5p, miR-142-3p, and Let-7d to dendritic cells (DCs) and T-helper 1 (Th1), reducing immune responses, and inhibiting the secretion of pro-inflammatory cytokines. These regulatory functions may be used to treat AF.<sup>[<xref rid="j_jtim-2023-0124_ref_147" ref-type="bibr">147</xref>]</sup> Xu <italic toggle="yes">et al</italic>. found that the delivery of Lv-Nrf2 exosomes could suppress AF-induced arrhythmias, myocardial fibrosis, apoptosis, and inflammation. Therefore, this study provides a potential novel approach for the therapies for AF.<sup>[<xref rid="j_jtim-2023-0124_ref_148" ref-type="bibr">148</xref>]</sup></p></sec><sec id="j_jtim-2023-0124_s_003_s_005"><title>Myocarditis</title><p>Myocarditis is defined as an inflammatory process of the myocardium. It can result in cardiac dysfunctions, such as progressively deteriorated diastolic and systolic function or arrhythmias.<sup>[<xref rid="j_jtim-2023-0124_ref_149" ref-type="bibr">149</xref>]</sup> The most severe form of myocarditis is fulminant myocarditis (FM), which develops rapidly and can lead to acute cardiac shocks.<sup>[<xref rid="j_jtim-2023-0124_ref_150" ref-type="bibr">150</xref>]</sup></p><p>Exosomes play important roles in myocarditis as well. Zhang <italic toggle="yes">et al</italic>. verified higher expression levels of hsamiR-146a-5p, hsa-miR-23a-3p, and hsa-miR-27a-3p in the exosomes of pediatric patients with FM using qRT-PCR, indicating that these three miRNAs can be used for the diagnosis of FM.<sup>[<xref rid="j_jtim-2023-0124_ref_151" ref-type="bibr">151</xref>]</sup> Another study determined that hsa-miR-155 and hsa-miR-320a provided an excellent diagnostic capability for patients with FM.<sup>[<xref rid="j_jtim-2023-0124_ref_152" ref-type="bibr">152</xref>]</sup></p><p>Viral infection is a major cause of myocarditis. Coxsackievirus B3 (CVB3), an enterovirus, is believed to be the most common causative agent of myocarditis.<sup>[<xref rid="j_jtim-2023-0124_ref_153" ref-type="bibr">153</xref>]</sup> Zhang <italic toggle="yes">et al</italic>. constructed an exosome-based anti-CVB3 vaccine (exo-VP1) that enhanced the resistance of mice to CVB3-induced viral myocarditis.<sup>[<xref rid="j_jtim-2023-0124_ref_154" ref-type="bibr">154</xref>]</sup> Gu <italic toggle="yes">et al</italic>. found that hucMSC-exosomes alleviated CVB3-induced myocarditis by activating the 5&#x02019; AMP-activated protein kinase (AMPK)/mTOR-mediated autophagy flux pathway to attenuate cardiomyocyte apoptosis, which will be beneficial for MSC-exosome therapy of myocarditis.<sup>[<xref rid="j_jtim-2023-0124_ref_155" ref-type="bibr">155</xref>]</sup></p><p>In summary, exosomes, especially exosomal miRNAs, are significant in these and possibly other CVDs. They may serve as a new strategy for diagnosing, treating and preventing CVDs in the future. For example, using exosomes as drug delivery vehicles is an important application of exosomes. In recent years, an increasing number of studies have revealed that exosomes could function as attractive biological vesicles for the delivery of biological therapeutics across different biological barriers to target cells <sup>[<xref rid="j_jtim-2023-0124_ref_004" ref-type="bibr">4</xref>, <xref rid="j_jtim-2023-0124_ref_156" ref-type="bibr">156</xref>, <xref rid="j_jtim-2023-0124_ref_157" ref-type="bibr">157</xref>]</sup>. Compared to available treatments, this method is non-invasive and may be more effective for CVDs. In the future, using exosomal delivery of drugs to treat CVD may have very good application prospects.</p><p>However, this new strategy is in its infancy. There are still several hurdles before achieving clinical application.<sup>[<xref rid="j_jtim-2023-0124_ref_158" ref-type="bibr">158</xref>,<xref rid="j_jtim-2023-0124_ref_159" ref-type="bibr">159</xref>]</sup> For example, the purification and separation technology of exosomes is not mature enough for clinical application.<sup>[<xref rid="j_jtim-2023-0124_ref_160" ref-type="bibr">160</xref>]</sup> Furthermore, exosomes contain a variety of biologically active substances, some of which may help inhibit CVDs, whereas others may cause adverse or side effects in the cardiac tissue.</p><p>In our opinion, the researchers should focus on improving the purification and separation technology of exosomes, thus removing harmful substances and making exosomes more suitable for treatment. Exosome therapies remain at the research stage, and the practical clinical results and potential side effects are unknown. Whether exosomes can be widely applied in clinical practice requires further research.</p></sec></sec><sec id="j_jtim-2023-0124_s_004"><title>Conclusions</title><p>Exosomes have received increasing attention partly because they are functional vehicles that carry a variety of lipids, proteins and nucleic acids and can deliver these cargos to the target cells they encounter. Because of this function, exosomes may be used for the diagnosis, prognosis and treatment of many diseases, including CVDs. Because of the exosomes&#x02019; biological function, they may function as biomarkers for the diagnosis and prognosis of CVDs and improve the therapies for CVDs. Many studies have demonstrated that exosomes are associated with CVDs, such as coronary artery disease, heart failure, cardiomyopathy, and atrial fibrillation. Exosomes participate in the progression or inhibition of these diseases mainly through the contents they deliver, especially different kinds of micro RNAs. However, because the application of exosomes in different CVDs is still an immature field, further research is needed.</p></sec></body><back><fn-group><fn fn-type="COI-statement" id="j_jtim-2023-0124_fn_001"><p>
<bold>Conflicts of Interest</bold>
</p><p>The authors declare that there are no competing interests associated with this manuscript.</p></fn></fn-group><ref-list><title>References</title><ref id="j_jtim-2023-0124_ref_001"><label>1</label><element-citation publication-type="journal"><name><surname>Kalluri</surname><given-names>R</given-names></name><name><surname>LeBleu</surname><given-names>VS</given-names></name><article-title>The biology, function, and biomedical applications of exosomes</article-title><source>Science</source><year>2020</year><volume>367</volume><fpage>eaau6977</fpage><pub-id pub-id-type="pmid">32029601</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_002"><label>2</label><element-citation publication-type="journal"><name><surname>Th&#x000e9;ry</surname><given-names>C</given-names></name><name><surname>Witwer</surname><given-names>KW</given-names></name><name><surname>Aikawa</surname><given-names>E</given-names></name><name><surname>Alcaraz</surname><given-names>MJ</given-names></name><name><surname>Anderson</surname><given-names>JD</given-names></name><name><surname>Andriantsitohaina</surname><given-names>R</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines.</article-title><source>J Extracell Vesicles</source><year>2018</year><volume>7</volume><fpage>1535750</fpage><pub-id pub-id-type="pmid">30637094</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_003"><label>3</label><element-citation publication-type="journal"><name><surname>Cocucci</surname><given-names>E</given-names></name><name><surname>Meldolesi</surname><given-names>J</given-names></name><article-title>Ectosomes and exosomes: shedding the confusion between extracellular vesicles</article-title><source>Trends Cell Biol</source><year>2015</year><volume>25</volume><fpage>364</fpage><comment>-</comment><lpage>372</lpage><pub-id pub-id-type="pmid">25683921</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_004"><label>4</label><element-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>WH</given-names></name><article-title>Exosomes: biogenesis, biologic function and clinical potential</article-title><source>Cell Biosci</source><year>2019</year><volume>9</volume><fpage>1</fpage><comment>-</comment><lpage>18</lpage><pub-id pub-id-type="pmid">30622695</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_005"><label>5</label><element-citation publication-type="journal"><name><surname>Waldenstr&#x000f6;m</surname><given-names>A</given-names></name><name><surname>Genneb&#x000e4;ck</surname><given-names>N</given-names></name><name><surname>Hellman</surname><given-names>U</given-names></name><name><surname>Ronquist</surname><given-names>G</given-names></name><article-title>Cardiomyocyte microvesicles contain DNA/RNA and convey biological messages to target cells</article-title><source>PloS one</source><year>2012</year><volume>7</volume><fpage>e34653</fpage><pub-id pub-id-type="pmid">22506041</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_006"><label>6</label><element-citation publication-type="journal"><name><surname>Valadi</surname><given-names>H</given-names></name><name><surname>Ekstr&#x000f6;m</surname><given-names>K</given-names></name><name><surname>Bossios</surname><given-names>A</given-names></name><name><surname>Sj&#x000f6;strand</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>L&#x000f6;tvall</surname><given-names>JO</given-names></name><article-title>Exosomemediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells</article-title><source>Nat. Cell Biol</source><year>2007</year><volume>9</volume><fpage>654</fpage><comment>-</comment><lpage>659</lpage><pub-id pub-id-type="pmid">17486113</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_007"><label>7</label><element-citation publication-type="journal"><name><surname>Vidal</surname><given-names>M</given-names></name><name><surname>Sainte&#x02010;Marie</surname><given-names>J</given-names></name><name><surname>Philippot</surname><given-names>JR</given-names></name><name><surname>Bienvenue</surname><given-names>A</given-names></name><article-title>Asymmetric distribution of phospholipids in the membrane of vesicles released during in vitro maturation of guinea pig reticulocytes: evidence precluding a role for &#x0201c;aminophospholipid translocase&#x0201d;</article-title><source>J Cell Physiol</source><year>1989</year><volume>140</volume><fpage>455</fpage><comment>-</comment><lpage>462</lpage><pub-id pub-id-type="pmid">2777884</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_008"><label>8</label><element-citation publication-type="journal"><name><surname>Simpson</surname><given-names>RJ</given-names></name><name><surname>Lim</surname><given-names>JW</given-names></name><name><surname>Moritz</surname><given-names>RL</given-names></name><name><surname>Mathivanan</surname><given-names>S</given-names></name><article-title>Exosomes: proteomic insights and diagnostic potential. Expert Rev</article-title><source>Proteom</source><year>2009</year><volume>6</volume><fpage>267</fpage><comment>-</comment><lpage>283</lpage></element-citation></ref><ref id="j_jtim-2023-0124_ref_009"><label>9</label><element-citation publication-type="journal"><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><article-title>Emerging role of exosomes in vascular diseases</article-title><source>Front Cardiovasc Med</source><year>2023</year><volume>10</volume></element-citation></ref><ref id="j_jtim-2023-0124_ref_010"><label>10</label><element-citation publication-type="journal"><name><surname>Mittelbrunn</surname><given-names>M</given-names></name><name><surname>Guti&#x000e9;rrez-V&#x000e1;zquez</surname><given-names>C</given-names></name><name><surname>Villarroya-Beltri</surname><given-names>C</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>S</given-names></name><name><surname>S&#x000e1;nchez-Cabo</surname><given-names>F</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>M&#x000c1;</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat</article-title><source>Commun</source><year>2011</year><volume>2</volume><fpage>282</fpage></element-citation></ref><ref id="j_jtim-2023-0124_ref_011"><label>11</label><element-citation publication-type="journal"><name><surname>Gangoda</surname><given-names>L</given-names></name><name><surname>Boukouris</surname><given-names>S</given-names></name><name><surname>Liem</surname><given-names>M</given-names></name><name><surname>Kalra</surname><given-names>H</given-names></name><name><surname>Mathivanan</surname><given-names>S</given-names></name><article-title>Extracellular vesicles including exosomes are mediators of signal transduction: are they protective or pathogenic?</article-title><source>Proteomics</source><year>2015</year><volume>15</volume><fpage>260</fpage><comment>-</comment><lpage>271</lpage><pub-id pub-id-type="pmid">25307053</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_012"><label>12</label><element-citation publication-type="journal"><name><surname>Greening</surname><given-names>DW</given-names></name><name><surname>Gopal</surname><given-names>SK</given-names></name><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Simpson</surname><given-names>RJ</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><article-title>Exosomes and their roles in immune regulation and cancer</article-title><source>Seminars in cell &#x00026; developmental biology: Elsevier</source><year>2015</year><fpage>72</fpage><comment>-</comment><lpage>81</lpage></element-citation></ref><ref id="j_jtim-2023-0124_ref_013"><label>13</label><element-citation publication-type="journal"><name><surname>Record</surname><given-names>M</given-names></name><name><surname>Poirot</surname><given-names>M</given-names></name><name><surname>Silvente-Poirot</surname><given-names>S</given-names></name><article-title>Emerging concepts on the role of exosomes in lipid metabolic diseases</article-title><source>Biochimie</source><year>2014</year><volume>96</volume><fpage>67</fpage><comment>-</comment><lpage>74</lpage><pub-id pub-id-type="pmid">23827857</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_014"><label>14</label><element-citation publication-type="journal"><name><surname>L&#x000e4;sser</surname><given-names>C</given-names></name><name><surname>O&#x02019;Neil</surname><given-names>SE</given-names></name><name><surname>Shelke</surname><given-names>GV</given-names></name><name><surname>Sihlbom</surname><given-names>C</given-names></name><name><surname>Hansson</surname><given-names>SF</given-names></name><name><surname>Gho</surname><given-names>YS</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Exosomes in the nose induce immune cell trafficking and harbour an altered protein cargo in chronic airway inflammation</article-title><source>J Transl Med</source><year>2016</year><volume>14</volume><fpage>1</fpage><comment>-</comment><lpage>14</lpage><pub-id pub-id-type="pmid">26727970</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_015"><label>15</label><element-citation publication-type="journal"><name><surname>Kishore</surname><given-names>R</given-names></name><name><surname>Garikipati</surname><given-names>VNS</given-names></name><name><surname>Gumpert</surname><given-names>A</given-names></name><article-title>Tiny shuttles for information transfer: exosomes in cardiac health and disease</article-title><source>J Cardiovasc Transl Res</source><year>2016</year><volume>9</volume><fpage>169</fpage><comment>-</comment><lpage>175</lpage><pub-id pub-id-type="pmid">26911150</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_016"><label>16</label><element-citation publication-type="journal"><name><surname>Balasubramanian</surname><given-names>S</given-names></name><name><surname>Rajasingh</surname><given-names>S</given-names></name><name><surname>Thangavel</surname><given-names>J</given-names></name><name><surname>Dawn</surname><given-names>B</given-names></name><name><surname>Rajasingh</surname><given-names>J</given-names></name><article-title>exosome function in miRNA-mediated paracrine effects</article-title><source>Mesenchymal Stem Cell Derived Exosomes: Elsevier;</source><year>2015</year><fpage>37</fpage><comment>-</comment><lpage>62</lpage></element-citation></ref><ref id="j_jtim-2023-0124_ref_017"><label>17</label><element-citation publication-type="journal"><name><surname>Samanta</surname><given-names>S</given-names></name><name><surname>Balasubramanian</surname><given-names>S</given-names></name><name><surname>Rajasingh</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>U</given-names></name><name><surname>Dhanasekaran</surname><given-names>A</given-names></name><name><surname>Dawn</surname><given-names>B</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>MicroRNA: a new therapeutic strategy for cardiovascular diseases</article-title><source>Trends Cardiovasc Med</source><year>2016</year><volume>26</volume><fpage>407</fpage><comment>-</comment><lpage>419</lpage><pub-id pub-id-type="pmid">27013138</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_018"><label>18</label><element-citation publication-type="journal"><name><surname>Xie</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>Q</given-names></name><name><surname>Yu</surname><given-names>Q</given-names></name><name><surname>Xia</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>S</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Cohort Profile: A Prospective Study of Gut Microbiota in Patients with Acute Ischemic Stroke</article-title><source>Advanced Gut &#x00026; Microbiome Research</source><year>2023</year><comment>2023</comment></element-citation></ref><ref id="j_jtim-2023-0124_ref_019"><label>19</label><element-citation publication-type="journal"><name><surname>Xue</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Sheng</surname><given-names>L</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Functional evaluation of intermediate coronary lesions with integrated computed tomography angiography and invasive angiography in patients with stable coronary artery disease</article-title><source>J Transl Int Med</source><year>2022</year><volume>10</volume><fpage>255</fpage><comment>-</comment><lpage>263</lpage><pub-id pub-id-type="pmid">36776233</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_020"><label>20</label><element-citation publication-type="journal"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Hua</surname><given-names>Y</given-names></name><name><surname>Qiao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Pang</surname><given-names>X</given-names></name><name><surname>Jia</surname><given-names>H</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>A novel wide-band dielectric imaging system for electro-anatomic mapping and monitoring in radiofrequency ablation and cryoablation</article-title><source>J Transl Int Med</source><year>2022</year><volume>10</volume><fpage>264</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">36776237</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_021"><label>21</label><element-citation publication-type="journal"><name><surname>Altesha</surname><given-names>MA</given-names></name><name><surname>Ni</surname><given-names>T</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><article-title>Circular RNA in cardiovascular disease</article-title><source>J Cell Physiol</source><year>2019</year><volume>234</volume><fpage>5588</fpage><comment>-</comment><lpage>5600</lpage><pub-id pub-id-type="pmid">30341894</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_022"><label>22</label><element-citation publication-type="journal"><name><surname>Laslett</surname><given-names>LJ</given-names></name><name><surname>Alagona</surname><given-names>P</given-names></name><name><surname>Clark</surname><given-names>BA</given-names></name><name><surname>Drozda</surname><given-names>JP</given-names></name><name><surname>Saldivar</surname><given-names>F</given-names></name><name><surname>Wilson</surname><given-names>SR</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology</article-title><source>J Am Coll Cardiol</source><year>2012</year><volume>60</volume><fpage>S1</fpage><comment>-</comment><lpage>S49</lpage><pub-id pub-id-type="pmid">23257320</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_023"><label>23</label><element-citation publication-type="journal"><name><surname>Dubois-Deruy</surname><given-names>E</given-names></name><name><surname>Peugnet</surname><given-names>V</given-names></name><name><surname>Turkieh</surname><given-names>A</given-names></name><name><surname>Pinet</surname><given-names>F</given-names></name><article-title>Oxidative stress in cardiovascular diseases</article-title><source>Antioxidants</source><year>2020</year><volume>9</volume><fpage>864</fpage><pub-id pub-id-type="pmid">32937950</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_024"><label>24</label><element-citation publication-type="journal"><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Blaha</surname><given-names>MJ</given-names></name><name><surname>Chiuve</surname><given-names>SE</given-names></name><name><surname>Cushman</surname><given-names>M</given-names></name><name><surname>Das</surname><given-names>SR</given-names></name><name><surname>Deo</surname><given-names>R</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Heart disease and stroke statistics&#x02014;2017 update: a report from the American Heart Association</article-title><source>Circulation</source><year>2017</year><volume>135</volume><fpage>e146</fpage><comment>-</comment><lpage>e603</lpage><pub-id pub-id-type="pmid">28122885</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_025"><label>25</label><element-citation publication-type="journal"><name><surname>Clerkin</surname><given-names>K</given-names></name><name><surname>Fried</surname><given-names>J</given-names></name><name><surname>Raikhelkar</surname><given-names>J</given-names></name><name><surname>Sayer</surname><given-names>G</given-names></name><name><surname>Griffin</surname><given-names>J</given-names></name><name><surname>Masoumi</surname><given-names>A</given-names></name><article-title>COVID- 19 and Cardiovascular Disease</article-title><source>Circulation</source><year>2020</year><volume>19</volume><fpage>20</fpage></element-citation></ref><ref id="j_jtim-2023-0124_ref_026"><label>26</label><element-citation publication-type="journal"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>G</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Relation between Cardiac Injury and Elevated Levels of Inflammatory Biomarkers in Patients with Severe COVID- 19</article-title><source>Cardiovasc Innov Appl</source><year>2021</year><volume>5</volume><fpage>165</fpage><comment>-</comment><lpage>172</lpage></element-citation></ref><ref id="j_jtim-2023-0124_ref_027"><label>27</label><element-citation publication-type="journal"><name><surname>Conti</surname><given-names>CR</given-names></name><article-title>Coronavirus 19 (some thoughts about the Disease)</article-title><source>Cardiovasc Innov Appl</source><year>2021</year><volume>5</volume><fpage>225</fpage><comment>-</comment><lpage>226</lpage></element-citation></ref><ref id="j_jtim-2023-0124_ref_028"><label>28</label><element-citation publication-type="journal"><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>XM</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Exosomes: novel biomarkers for clinical diagnosis</article-title><source>Sci World</source><year>2015</year><comment>2015</comment></element-citation></ref><ref id="j_jtim-2023-0124_ref_029"><label>29</label><element-citation publication-type="journal"><name><surname>Ibrahim</surname><given-names>A</given-names></name><name><surname>Marb&#x000e1;n</surname><given-names>E</given-names></name><article-title>Exosomes: fundamental biology and roles in cardiovascular physiology</article-title><source>Annu Rev Physiol</source><year>2016</year><volume>78</volume><fpage>67</fpage><pub-id pub-id-type="pmid">26667071</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_030"><label>30</label><element-citation publication-type="journal"><name><surname>Bellin</surname><given-names>G</given-names></name><name><surname>Gardin</surname><given-names>C</given-names></name><name><surname>Ferroni</surname><given-names>L</given-names></name><name><surname>Chachques</surname><given-names>JC</given-names></name><name><surname>Rogante</surname><given-names>M</given-names></name><name><surname>Mitre&#x0010d;i&#x00107;</surname><given-names>D</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Exosome in cardiovascular diseases: a complex world full of hope</article-title><source>Cells</source><year>2019</year><volume>8</volume><fpage>166</fpage><pub-id pub-id-type="pmid">30781555</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_031"><label>31</label><element-citation publication-type="journal"><name><surname>Harding</surname><given-names>C</given-names></name><name><surname>Heuser</surname><given-names>J</given-names></name><name><surname>Stahl</surname><given-names>P</given-names></name><article-title>Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes</article-title><source>J Cell Biol</source><year>1983</year><volume>97</volume><fpage>329</fpage><comment>-</comment><lpage>339</lpage><pub-id pub-id-type="pmid">6309857</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_032"><label>32</label><element-citation publication-type="journal"><name><surname>Pan</surname><given-names>B-T</given-names></name><name><surname>Teng</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Adam</surname><given-names>M</given-names></name><name><surname>Johnstone</surname><given-names>RM</given-names></name><article-title>Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes</article-title><source>J Cell Biol</source><year>1985</year><volume>101</volume><fpage>942</fpage><comment>-</comment><lpage>948</lpage><pub-id pub-id-type="pmid">2993317</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_033"><label>33</label><element-citation publication-type="journal"><name><surname>Johnstone</surname><given-names>RM</given-names></name><name><surname>Adam</surname><given-names>M</given-names></name><name><surname>Hammond</surname><given-names>J</given-names></name><name><surname>Orr</surname><given-names>L</given-names></name><name><surname>Turbide</surname><given-names>C</given-names></name><article-title>Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes)</article-title><source>J Biol Chem</source><year>1987</year><volume>262</volume><fpage>9412</fpage><lpage>9420</lpage><pub-id pub-id-type="pmid">3597417</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_034"><label>34</label><element-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Bi</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><article-title>Exosome: a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications</article-title><source>Int J Nanomed</source><year>2020</year><volume>15</volume><fpage>6917</fpage></element-citation></ref><ref id="j_jtim-2023-0124_ref_035"><label>35</label><element-citation publication-type="journal"><name><surname>Batista</surname><given-names>BS</given-names></name><name><surname>Eng</surname><given-names>WS</given-names></name><name><surname>Pilobello</surname><given-names>KT</given-names></name><name><surname>Hendricks-Mu&#x000f1;oz</surname><given-names>KD</given-names></name><name><surname>Mahal</surname><given-names>LK</given-names></name><article-title>Identification of a conserved glycan signature for microvesicles</article-title><source>J Proteome Res</source><year>2011</year><volume>10</volume><fpage>4624</fpage><comment>-</comment><lpage>4633</lpage><pub-id pub-id-type="pmid">21859146</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_036"><label>36</label><element-citation publication-type="journal"><name><surname>Tschuschke</surname><given-names>M</given-names></name><name><surname>Kocherova</surname><given-names>I</given-names></name><name><surname>Bryja</surname><given-names>A</given-names></name><name><surname>Mozdziak</surname><given-names>P</given-names></name><name><surname>Angelova</surname><given-names>Volponi A</given-names></name><name><surname>Janowicz</surname><given-names>K</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Inclusion biogenesis, methods of isolation and clinical application of human cellular exosomes</article-title><source>J Clin Med</source><year>2020</year><volume>9</volume><fpage>436</fpage><pub-id pub-id-type="pmid">32041096</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_037"><label>37</label><element-citation publication-type="journal"><name><surname>Hanson</surname><given-names>PI</given-names></name><name><surname>Cashikar</surname><given-names>A</given-names></name><article-title>Multivesicular body morphogenesis</article-title><source>Annu Rev Cell Dev Biol</source><year>2012</year><volume>28</volume><fpage>337</fpage><comment>-</comment><lpage>362</lpage><pub-id pub-id-type="pmid">22831642</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_038"><label>38</label><element-citation publication-type="journal"><name><surname>Hurley</surname><given-names>JH</given-names></name><article-title>ESCRT s are everywhere</article-title><source>EMBO J</source><year>2015</year><volume>34</volume><fpage>2398</fpage><comment>-</comment><lpage>2407</lpage><pub-id pub-id-type="pmid">26311197</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_039"><label>39</label><element-citation publication-type="journal"><name><surname>Marsh</surname><given-names>M</given-names></name><name><surname>van Meer</surname><given-names>G</given-names></name><article-title>No ESCRTs for exosomes</article-title><source>Science</source><year>2008</year><volume>319</volume><fpage>11911192</fpage></element-citation></ref><ref id="j_jtim-2023-0124_ref_040"><label>40</label><element-citation publication-type="journal"><name><surname>Rana</surname><given-names>S</given-names></name><name><surname>Z&#x000f6;ller</surname><given-names>M</given-names></name><article-title>Exosome target cell selection and the importance of exosomal tetraspanins: a hypothesis</article-title><source>Biochem Soc Trans</source><year>2011</year><volume>39</volume><fpage>559</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">21428939</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_041"><label>41</label><element-citation publication-type="journal"><name><surname>de Gassart</surname><given-names>A</given-names></name><name><surname>G&#x000e9;minard</surname><given-names>C</given-names></name><name><surname>F&#x000e9;vrier</surname><given-names>B</given-names></name><name><surname>Raposo</surname><given-names>G</given-names></name><name><surname>Vidal</surname><given-names>M</given-names></name><article-title>Lipid raft-associated protein sorting in exosomes</article-title><source>Blood</source><year>2003</year><volume>102</volume><fpage>4336</fpage><comment>-</comment><lpage>4344</lpage><pub-id pub-id-type="pmid">12881314</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_042"><label>42</label><element-citation publication-type="journal"><name><surname>Van Niel</surname><given-names>G</given-names></name><name><surname>d&#x02019;Angelo</surname><given-names>G</given-names></name><name><surname>Raposo</surname><given-names>G</given-names></name><article-title>Shedding light on the cell biology of extracellular vesicles</article-title><source>Nat Rev Mol Cell Biol</source><year>2018</year><volume>19</volume><fpage>213</fpage><comment>-</comment><lpage>228</lpage><pub-id pub-id-type="pmid">29339798</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_043"><label>43</label><element-citation publication-type="journal"><name><surname>D&#x02019;Souza-Schorey</surname><given-names>C</given-names></name><name><surname>Clancy</surname><given-names>JW</given-names></name><article-title>Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers</article-title><source>Genes Dev</source><year>2012</year><volume>26</volume><fpage>1287</fpage><comment>-</comment><lpage>1299</lpage><pub-id pub-id-type="pmid">22713869</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_044"><label>44</label><element-citation publication-type="journal"><name><surname>Pasquet</surname><given-names>JM</given-names></name><name><surname>Dachary&#x02010;Prigent</surname><given-names>J</given-names></name><name><surname>Nurden</surname><given-names>AT</given-names></name><article-title>Calcium influx is a determining factor of calpain activation and microparticle formation in platelets</article-title><source>Eur J Biochem</source><year>1996</year><volume>239</volume><fpage>647</fpage><comment>-</comment><lpage>654</lpage><pub-id pub-id-type="pmid">8774708</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_045"><label>45</label><element-citation publication-type="journal"><name><surname>Hutagalung</surname><given-names>AH</given-names></name><name><surname>Novick</surname><given-names>PJ</given-names></name><article-title>Role of Rab GTPases in membrane traffic and cell physiology</article-title><source>Physiol Rev</source><year>2011</year><volume>91</volume><fpage>119</fpage><comment>-</comment><lpage>149</lpage><pub-id pub-id-type="pmid">21248164</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_046"><label>46</label><element-citation publication-type="journal"><name><surname>Bonifacino</surname><given-names>JS</given-names></name><name><surname>Glick</surname><given-names>BS</given-names></name><article-title>The mechanisms of vesicle budding and fusion</article-title><source>Cell</source><year>2004</year><volume>116</volume><fpage>153</fpage><comment>-</comment><lpage>166</lpage><pub-id pub-id-type="pmid">14744428</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_047"><label>47</label><element-citation publication-type="journal"><name><surname>Fader</surname><given-names>CM</given-names></name><name><surname>S&#x000e1;nchez</surname><given-names>DG</given-names></name><name><surname>Mestre</surname><given-names>MB</given-names></name><name><surname>Colombo</surname><given-names>MI</given-names></name><article-title>TI-VAMP/VAMP7 and VAMP3/cellubrevin: two v-SNARE proteins involved in specific steps of the autophagy/multivesicular body pathways</article-title><source>Biochimica et Biophysica Acta (BBA)-Mol Cell Res</source><year>2009</year><volume>1793</volume><fpage>1901</fpage><comment>-</comment><lpage>1916</lpage></element-citation></ref><ref id="j_jtim-2023-0124_ref_048"><label>48</label><element-citation publication-type="journal"><name><surname>Gross</surname><given-names>JC</given-names></name><name><surname>Chaudhary</surname><given-names>V</given-names></name><name><surname>Bartscherer</surname><given-names>K</given-names></name><name><surname>Boutros</surname><given-names>M</given-names></name><article-title>Active Wnt proteins are secreted on exosomes</article-title><source>Nat Cell Biol</source><year>2012</year><volume>14</volume><fpage>1036</fpage><comment>-</comment><lpage>1045</lpage><pub-id pub-id-type="pmid">22983114</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_049"><label>49</label><element-citation publication-type="journal"><name><surname>Nanbo</surname><given-names>A</given-names></name><name><surname>Kawanishi</surname><given-names>E</given-names></name><name><surname>Yoshida</surname><given-names>R</given-names></name><name><surname>Yoshiyama</surname><given-names>H</given-names></name><article-title>Exosomes derived from Epstein-Barr virus-infected cells are internalized via caveola-dependent endocytosis and promote phenotypic modulation in target cells</article-title><source>J Virol</source><year>2013</year><volume>87</volume><fpage>10334</fpage><comment>-</comment><lpage>10347</lpage><pub-id pub-id-type="pmid">23864627</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_050"><label>50</label><element-citation publication-type="journal"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Qian</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><article-title>Exosomes in cancer: small particle, big player</article-title><source>J Hematol Oncol</source><year>2015</year><volume>8</volume><fpage>1</fpage><comment>-</comment><lpage>13</lpage><pub-id pub-id-type="pmid">25622682</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_051"><label>51</label><element-citation publication-type="book"><name><surname>Mincheva-Nilsson</surname><given-names>L</given-names></name><name><surname>Baranov</surname><given-names>V</given-names></name><source>Cancer exosomes and NKG2D receptor&#x02013;ligand interactions: Impairing NKG2D-mediated cytotoxicity and anti-tumour immune surveillance. Semin Cancer Biol</source><publisher-name>Elsevier</publisher-name><year>2014</year><fpage>24</fpage><lpage>30</lpage></element-citation></ref><ref id="j_jtim-2023-0124_ref_052"><label>52</label><element-citation publication-type="journal"><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Regnault</surname><given-names>A</given-names></name><name><surname>Lozier</surname><given-names>A</given-names></name><name><surname>Wolfers</surname><given-names>J</given-names></name><name><surname>Flament</surname><given-names>C</given-names></name><name><surname>Tenza</surname><given-names>D</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes</article-title><source>Nat Med</source><year>1998</year><volume>4</volume><fpage>594</fpage><comment>-</comment><lpage>600</lpage><pub-id pub-id-type="pmid">9585234</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_053"><label>53</label><element-citation publication-type="journal"><name><surname>Tkach</surname><given-names>M</given-names></name><name><surname>Kowal</surname><given-names>J</given-names></name><name><surname>Zucchetti</surname><given-names>AE</given-names></name><name><surname>Enserink</surname><given-names>L</given-names></name><name><surname>Jouve</surname><given-names>M</given-names></name><name><surname>Lankar</surname><given-names>D</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Qualitative differences in T&#x02010;cell activation by dendritic cell&#x02010;derived extracellular vesicle subtypes</article-title><source>EMBO J</source><year>2017</year><volume>36</volume><fpage>3012</fpage><comment>-</comment><lpage>3028</lpage><pub-id pub-id-type="pmid">28923825</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_054"><label>54</label><element-citation publication-type="journal"><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Schorey</surname><given-names>JS</given-names></name><article-title>Exosomes carrying mycobacterial antigens can protect mice against M ycobacterium tuberculosis infection</article-title><source>Eur J Immunol</source><year>2013</year><volume>43</volume><fpage>3279</fpage><comment>-</comment><lpage>3290</lpage><pub-id pub-id-type="pmid">23943377</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_055"><label>55</label><element-citation publication-type="journal"><name><surname>Ratajczak</surname><given-names>J</given-names></name><name><surname>Miekus</surname><given-names>K</given-names></name><name><surname>Kucia</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Reca</surname><given-names>R</given-names></name><name><surname>Dvorak</surname><given-names>P</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery</article-title><source>Leukemia</source><year>2006</year><volume>20</volume><fpage>847</fpage><comment>-</comment><lpage>856</lpage><pub-id pub-id-type="pmid">16453000</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_056"><label>56</label><element-citation publication-type="journal"><name><surname>Gatti</surname><given-names>S</given-names></name><name><surname>Bruno</surname><given-names>S</given-names></name><name><surname>Deregibus</surname><given-names>MC</given-names></name><name><surname>Sordi</surname><given-names>A</given-names></name><name><surname>Cantaluppi</surname><given-names>V</given-names></name><name><surname>Tetta</surname><given-names>C</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia&#x02013;reperfusion-induced acute and chronic kidney injury</article-title><source>Nephrol Dial Transplant</source><year>2011</year><volume>26</volume><fpage>1474</fpage><comment>-</comment><lpage>1483</lpage><pub-id pub-id-type="pmid">21324974</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_057"><label>57</label><element-citation publication-type="journal"><name><surname>Xiang</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Zhai</surname><given-names>G</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>The diagnostic and prognostic value of serum exosome&#x02010;derived carbamoyl phosphate synthase 1 in HEV&#x02010;related acute liver failure patients</article-title><source>J Med Virol</source><year>2022</year><volume>94</volume><fpage>5015</fpage><comment>-</comment><lpage>5025</lpage><pub-id pub-id-type="pmid">35760734</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_058"><label>58</label><element-citation publication-type="journal"><name><surname>Xiang</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Serum extracellular vesicle&#x02010;derived ASS1 is a promising predictor for the occurrence of HEV&#x02010;ALF</article-title><source>J Med Virol</source><year>2023</year><volume>95</volume><fpage>e28425</fpage><pub-id pub-id-type="pmid">36562411</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_059"><label>59</label><element-citation publication-type="journal"><name><surname>Wolfe</surname><given-names>W</given-names></name><name><surname>Xiang</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Yao</surname><given-names>M</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>The Challenge of Applications of Probiotics in Gastrointestinal Diseases</article-title><source>Advanced Gut &#x00026; Microbiome Research</source><year>2023</year><comment>2023</comment></element-citation></ref><ref id="j_jtim-2023-0124_ref_060"><label>60</label><element-citation publication-type="journal"><name><surname>Howitt</surname><given-names>J</given-names></name><name><surname>Hill</surname><given-names>AF</given-names></name><article-title>Exosomes in the pathology of neurodegenerative diseases</article-title><source>J Biol Chem</source><year>2016</year><volume>291</volume><fpage>26589</fpage><comment>-</comment><lpage>26597</lpage><pub-id pub-id-type="pmid">27852825</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_061"><label>61</label><element-citation publication-type="journal"><name><surname>Ren</surname><given-names>R</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>The China Alzheimer Report 2022</article-title><source>Gen Psychiatr</source><year>2022</year><volume>35</volume><fpage>e100751</fpage><pub-id pub-id-type="pmid">35372787</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_062"><label>62</label><element-citation publication-type="journal"><name><surname>Islam</surname><given-names>SS</given-names></name><name><surname>Neargarder</surname><given-names>S</given-names></name><name><surname>Kinger</surname><given-names>SB</given-names></name><name><surname>Fox-Fuller</surname><given-names>JT</given-names></name><name><surname>Salazar</surname><given-names>RD</given-names></name><name><surname>Cronin-Golomb</surname><given-names>A</given-names></name><article-title>Perceived stigma and quality of life in Parkinson's disease with additional health conditions</article-title><source>Gen Psychiatr</source><year>2022</year><volume>35</volume><fpage>e100653</fpage><pub-id pub-id-type="pmid">35846485</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_063"><label>63</label><element-citation publication-type="journal"><name><surname>Abd</surname><given-names>Elmageed ZY</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Thomas</surname><given-names>R</given-names></name><name><surname>Ranjan</surname><given-names>M</given-names></name><name><surname>Mondal</surname><given-names>D</given-names></name><name><surname>Moroz</surname><given-names>K</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes</article-title><source>Stem Cells</source><year>2014</year><volume>32</volume><fpage>983</fpage><comment>-</comment><lpage>997</lpage><pub-id pub-id-type="pmid">24715691</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_064"><label>64</label><element-citation publication-type="journal"><name><surname>Bang</surname><given-names>C</given-names></name><name><surname>Batkai</surname><given-names>S</given-names></name><name><surname>Dangwal</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>SK</given-names></name><name><surname>Foinquinos</surname><given-names>A</given-names></name><name><surname>Holzmann</surname><given-names>A</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Cardiac fibroblast&#x02013;derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy</article-title><source>J Clin Investig</source><year>2014</year><volume>124</volume><fpage>2136</fpage><comment>-</comment><lpage>2146</lpage><pub-id pub-id-type="pmid">24743145</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_065"><label>65</label><element-citation publication-type="journal"><name><surname>Xiong</surname><given-names>C-q</given-names></name><name><surname>Zhou</surname><given-names>H-c</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>N-Z</given-names></name><article-title>The protective effects and the involved mechanisms of tanshinone IIA on sepsis-induced brain damage in mice</article-title><source>Inflammation</source><year>2019</year><volume>42</volume><fpage>354</fpage><comment>-</comment><lpage>364</lpage><pub-id pub-id-type="pmid">30255286</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_066"><label>66</label><element-citation publication-type="journal"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name><name><surname>Ling</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Altered faecal microbiota on the expression of Th cells responses in the exacerbation of patients with hepatitis E infection</article-title><source>J Viral Hepat</source><year>2020</year><volume>27</volume><fpage>1243</fpage><comment>-</comment><lpage>1252</lpage><pub-id pub-id-type="pmid">32500937</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_067"><label>67</label><element-citation publication-type="journal"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>YW</given-names></name><name><surname>Shao</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>SH</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>QH</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Gut microbiota dysbiosis in Chinese children with type 1 diabetes mellitus: An observational study</article-title><source>World J Gastroenterol</source><year>2021</year><volume>27</volume><fpage>2394</fpage><pub-id pub-id-type="pmid">34040330</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_068"><label>68</label><element-citation publication-type="journal"><name><surname>Gould</surname><given-names>D</given-names></name><name><surname>Favorov</surname><given-names>P</given-names></name><article-title>Vectors for the treatment of autoimmune disease</article-title><source>Gene Ther</source><year>2003</year><volume>10</volume><fpage>912</fpage><comment>-</comment><lpage>927</lpage><pub-id pub-id-type="pmid">12732876</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_069"><label>69</label><element-citation publication-type="journal"><name><surname>Yin</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>LH</given-names></name><article-title>Extracellular vesicles: Targeting the heart</article-title><source>Front Cardiovasc Med</source><year>2022</year><volume>9</volume></element-citation></ref><ref id="j_jtim-2023-0124_ref_070"><label>70</label><element-citation publication-type="journal"><name><surname>Spigel</surname><given-names>DR</given-names></name><name><surname>Vicente</surname><given-names>D</given-names></name><name><surname>Ciuleanu</surname><given-names>TE</given-names></name><name><surname>Gettinger</surname><given-names>S</given-names></name><name><surname>Peters</surname><given-names>S</given-names></name><name><surname>Horn</surname><given-names>L</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331</article-title><source>Annals of oncology: official journal of the European Society for Medical Oncology</source><year>2021</year><volume>32</volume><fpage>631</fpage><comment>-</comment><lpage>641</lpage><pub-id pub-id-type="pmid">33539946</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_071"><label>71</label><element-citation publication-type="journal"><name><surname>Yuan</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><article-title>New developments in exosomal lncRNAs in cardiovascular diseases</article-title><source>Front Cardiovasc Med</source><year>2021</year><volume>8</volume><fpage>709169</fpage><pub-id pub-id-type="pmid">34307511</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_072"><label>72</label><element-citation publication-type="journal"><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Cheng</surname><given-names>K</given-names></name><name><surname>Zou</surname><given-names>T</given-names></name><name><surname>Pang</surname><given-names>Y</given-names></name><name><surname>Ling</surname><given-names>Y</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Exosomes and exosomal non-coding RNAs are novel promises for the mechanism-based diagnosis and treatments of atrial fibrillation</article-title><source>Front Cardiovasc Med</source><year>2021</year><volume>8</volume><fpage>782451</fpage><pub-id pub-id-type="pmid">34926627</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_073"><label>73</label><element-citation publication-type="journal"><name><surname>Cervio</surname><given-names>E</given-names></name><name><surname>Barile</surname><given-names>L</given-names></name><name><surname>Moccetti</surname><given-names>T</given-names></name><name><surname>Vassalli</surname><given-names>G</given-names></name><article-title>Exosomes for intramyocardial intercellular communication</article-title><source>Stem Cells Int</source><year>2015</year><comment>2015</comment></element-citation></ref><ref id="j_jtim-2023-0124_ref_074"><label>74</label><element-citation publication-type="journal"><name><surname>Thomas</surname><given-names>H</given-names></name><name><surname>Diamond</surname><given-names>J</given-names></name><name><surname>Vieco</surname><given-names>A</given-names></name><name><surname>Chaudhuri</surname><given-names>S</given-names></name><name><surname>Shinnar</surname><given-names>E</given-names></name><name><surname>Cromer</surname><given-names>S</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Global atlas of cardiovascular disease</article-title><source>Glob Heart</source><year>2018</year><volume>13</volume><fpage>143</fpage><comment>-</comment><lpage>163</lpage><pub-id pub-id-type="pmid">30301680</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_075"><label>75</label><element-citation publication-type="journal"><name><surname>Malakar</surname><given-names>AK</given-names></name><name><surname>Choudhury</surname><given-names>D</given-names></name><name><surname>Halder</surname><given-names>B</given-names></name><name><surname>Paul</surname><given-names>P</given-names></name><name><surname>Uddin</surname><given-names>A</given-names></name><name><surname>Chakraborty</surname><given-names>S</given-names></name><article-title>A review on coronary artery disease, its risk factors, and therapeutics</article-title><source>J Cell Physiol</source><year>2019</year><volume>234</volume><fpage>16812</fpage><comment>-</comment><lpage>16823</lpage><pub-id pub-id-type="pmid">30790284</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_076"><label>76</label><element-citation publication-type="journal"><name><surname>S&#x000e1;nchez</surname><given-names>Y</given-names></name><name><surname>Huarte</surname><given-names>M</given-names></name><article-title>Long non-coding RNAs: challenges for diagnosis and therapies</article-title><source>Nucleic Acid Ther</source><year>2013</year><volume>23</volume><fpage>15</fpage><comment>-</comment><lpage>20</lpage><pub-id pub-id-type="pmid">23391415</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_077"><label>77</label><element-citation publication-type="journal"><name><surname>Lu</surname><given-names>X</given-names></name><article-title>The role of exosomes and exosome-derived microRNAs in atherosclerosis</article-title><source>Curr Pharm Des</source><year>2017</year><volume>23</volume><fpage>6182</fpage><comment>-</comment><lpage>6193</lpage><pub-id pub-id-type="pmid">28412904</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_078"><label>78</label><element-citation publication-type="journal"><name><surname>Dykes</surname><given-names>IM</given-names></name><article-title>Exosomes in cardiovascular medicine</article-title><source>Cardiol Ther</source><year>2017</year><volume>6</volume><fpage>225</fpage><comment>-</comment><lpage>237</lpage><pub-id pub-id-type="pmid">28526928</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_079"><label>79</label><element-citation publication-type="journal"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Zheng</surname><given-names>P</given-names></name><name><surname>Zeng</surname><given-names>J</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Exosomal lncRNA GAS5 regulates the apoptosis of macrophages and vascular endothelial cells in atherosclerosis</article-title><source>PloS one</source><year>2017</year><volume>12</volume><fpage>e0185406</fpage><pub-id pub-id-type="pmid">28945793</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_080"><label>80</label><element-citation publication-type="journal"><name><surname>Liang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Lian</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>N</given-names></name><article-title>Circulating exosomal SOCS2-AS1 acts as a novel biomarker in predicting the diagnosis of coronary artery disease</article-title><source>Biomed Res Int</source><year>2020</year><comment>2020</comment></element-citation></ref><ref id="j_jtim-2023-0124_ref_081"><label>81</label><element-citation publication-type="journal"><name><surname>Ling</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>C</given-names></name><article-title>Serum exosomal MicroRNA-21, MicroRNA-126, and PTEN are novel biomarkers for diagnosis of acute coronary syndrome. Front</article-title><source>Physiol</source><year>2020</year><volume>11</volume><fpage>654</fpage></element-citation></ref><ref id="j_jtim-2023-0124_ref_082"><label>82</label><element-citation publication-type="journal"><name><surname>Bi</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Lv</surname><given-names>Z</given-names></name><name><surname>Xing</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><article-title>Correlation between serum exosome derived miR-208a and acute coronary syndrome</article-title><source>Int J Clin Exp Med</source><year>2015</year><volume>8</volume><fpage>4275</fpage><pub-id pub-id-type="pmid">26064341</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_083"><label>83</label><element-citation publication-type="journal"><name><surname>Li</surname><given-names>L-J</given-names></name><name><surname>Gu</surname><given-names>Y-J</given-names></name><name><surname>Wang</surname><given-names>L-Q</given-names></name><name><surname>Wan</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>H-W</given-names></name><name><surname>Yang</surname><given-names>X-N</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Serum exosomal microRNA-146a as a novel diagnostic biomarker for acute coronary syndrome</article-title><source>J Thorac Dis</source><year>2021</year><volume>13</volume><fpage>3105</fpage><pub-id pub-id-type="pmid">34164201</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_084"><label>84</label><element-citation publication-type="journal"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhi</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Fan</surname><given-names>W</given-names></name><name><surname>Miao</surname><given-names>Q</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Diagnostic value of using exosome&#x02011;derived cysteine&#x02011;rich protein 61 as biomarkers for acute coronary syndrome</article-title><source>Exp Ther Med</source><year>2021</year><volume>22</volume><fpage>1</fpage><comment>-</comment><lpage>11</lpage></element-citation></ref><ref id="j_jtim-2023-0124_ref_085"><label>85</label><element-citation publication-type="journal"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Ye</surname><given-names>Z-Q</given-names></name><name><surname>Li</surname><given-names>Z-W</given-names></name><name><surname>Zhao</surname><given-names>C-X</given-names></name><name><surname>Chen</surname><given-names>G-J</given-names></name><name><surname>Zhou</surname><given-names>J-Z</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Wen-yang Huoxue Jiedu formula inhibits thin-cap fibroatheroma plaque formation via the VEGF/VEGFR signaling pathway</article-title><source>J Ethnopharmacol</source><year>2018</year><volume>219</volume><fpage>213</fpage><comment>-</comment><lpage>221</lpage><pub-id pub-id-type="pmid">29551453</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_086"><label>86</label><element-citation publication-type="journal"><name><surname>Linton</surname><given-names>MF</given-names></name><name><surname>Moslehi</surname><given-names>JJ</given-names></name><name><surname>Babaev</surname><given-names>VR</given-names></name><article-title>Akt signaling in macrophage polarization, survival, and atherosclerosis</article-title><source>Int J Mol Sci</source><year>2019</year><volume>20</volume><fpage>2703</fpage><pub-id pub-id-type="pmid">31159424</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_087"><label>87</label><element-citation publication-type="journal"><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>ApoM-S1P modulates Ox-LDL-induced inflammation through the PI3K/Akt signaling pathway in HUVECs</article-title><source>Inflammation</source><year>2019</year><volume>42</volume><fpage>606</fpage><comment>-</comment><lpage>617</lpage><pub-id pub-id-type="pmid">30377890</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_088"><label>88</label><element-citation publication-type="journal"><name><surname>Sun</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Ji</surname><given-names>Z</given-names></name><article-title>Up-regulation of MIAT aggravates the atherosclerotic damage in atherosclerosis mice through the activation of PI3K/Akt signaling pathway</article-title><source>Drug Deliv</source><year>2019</year><volume>26</volume><fpage>641</fpage><comment>-</comment><lpage>649</lpage><pub-id pub-id-type="pmid">31237148</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_089"><label>89</label><element-citation publication-type="journal"><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Liang</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Circulating exosomal miRNAs as novel biomarkers for stable coronary artery disease</article-title><source>Biomed Res Int</source><year>2020</year><comment>2020</comment></element-citation></ref><ref id="j_jtim-2023-0124_ref_090"><label>90</label><element-citation publication-type="journal"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>Q</given-names></name><name><surname>Bao</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis</article-title><source>Cell Res</source><year>2015</year><volume>25</volume><fpage>981</fpage><comment>-</comment><lpage>984</lpage><pub-id pub-id-type="pmid">26138677</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_091"><label>91</label><element-citation publication-type="journal"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Piao</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Circular RNAs as potential biomarkers and therapeutics for cardiovascular disease</article-title><source>Peer J</source><year>2019</year><volume>7</volume><fpage>e6831</fpage><pub-id pub-id-type="pmid">31119072</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_092"><label>92</label><element-citation publication-type="journal"><name><surname>Cai</surname><given-names>JJ</given-names></name><name><surname>Jiang</surname><given-names>HH</given-names></name><article-title>Application Potential of Probiotics in Acute Myocardial Infarction</article-title><source>Cardiovasc Innov Appl</source><year>2022</year><volume>7</volume><fpage>1</fpage><comment>-</comment><lpage>9</lpage></element-citation></ref><ref id="j_jtim-2023-0124_ref_093"><label>93</label><element-citation publication-type="journal"><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Jia</surname><given-names>Z</given-names></name><name><surname>Trush</surname><given-names>MA</given-names></name><article-title>Defining ROS in biology and medicine</article-title><source>Reactive oxygen species (Apex, NC)</source><year>2016</year><volume>1</volume><fpage>9</fpage></element-citation></ref><ref id="j_jtim-2023-0124_ref_094"><label>94</label><element-citation publication-type="journal"><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Lian</surname><given-names>G</given-names></name><article-title>ROS and diseases: Role in metabolism and energy supply</article-title><source>Mol Cell Biochem</source><year>2020</year><volume>467</volume><fpage>1</fpage><comment>-</comment><lpage>12</lpage><pub-id pub-id-type="pmid">31813106</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_095"><label>95</label><element-citation publication-type="journal"><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Kataoka</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Liang</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>ZP</given-names></name><name><surname>Gu</surname><given-names>F</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Therapeutic role of miR- 19a/19b in cardiac regeneration and protection from myocardial infarction</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><fpage>1</fpage><comment>-</comment><lpage>15</lpage><pub-id pub-id-type="pmid">30602773</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_096"><label>96</label><element-citation publication-type="journal"><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Kim</surname><given-names>HW</given-names></name><name><surname>Gong</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Millard</surname><given-names>RW</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Exosomes secreted from GATA-4 overexpressing mesenchymal stem cells serve as a reservoir of anti-apoptotic microRNAs for cardioprotection</article-title><source>Int J Cardiol</source><year>2015</year><volume>182</volume><fpage>349</fpage><comment>-</comment><lpage>360</lpage><pub-id pub-id-type="pmid">25590961</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_097"><label>97</label><element-citation publication-type="journal"><name><surname>Ong</surname><given-names>S-G</given-names></name><name><surname>Hausenloy</surname><given-names>DJ</given-names></name><article-title>Hypoxia-inducible factor as a therapeutic target for cardioprotection</article-title><source>Pharmacol Ther</source><year>2012</year><volume>136</volume><fpage>69</fpage><comment>-</comment><lpage>81</lpage><pub-id pub-id-type="pmid">22800800</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_098"><label>98</label><element-citation publication-type="journal"><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Zuo</surname><given-names>J</given-names></name><article-title>Emerging roles of miR-210 and other non-coding RNAs in the hypoxic response</article-title><source>Acta Biochim Biophys Sin</source><year>2014</year><volume>46</volume><fpage>220</fpage><comment>-</comment><lpage>232</lpage><pub-id pub-id-type="pmid">24395300</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_099"><label>99</label><element-citation publication-type="journal"><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><article-title>microRNA-133: expression, function and therapeutic potential in muscle diseases and cancer</article-title><source>Curr Drug Targets</source><year>2014</year><volume>15</volume><fpage>817</fpage><comment>-</comment><lpage>828</lpage><pub-id pub-id-type="pmid">24975488</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_100"><label>100</label><element-citation publication-type="journal"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>ZA</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>MicroRNA-133 overexpression promotes the therapeutic efficacy of mesenchymal stem cells on acute myocardial infarction</article-title><source>Stem Cell Res Ther</source><year>2017</year><volume>8</volume><fpage>1</fpage><comment>-</comment><lpage>11</lpage><pub-id pub-id-type="pmid">28057078</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_101"><label>101</label><element-citation publication-type="journal"><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>You</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><article-title>MiRNAs as biomarkers of myocardial infarction: a meta-analysis</article-title><source>PloS one</source><year>2014</year><volume>9</volume><fpage>e88566</fpage><pub-id pub-id-type="pmid">24533109</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_102"><label>102</label><element-citation publication-type="journal"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Xue</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Chu</surname><given-names>X</given-names></name><name><surname>Xin</surname><given-names>D</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Exosomes derived from mesenchymal stem cells attenuate the progression of atherosclerosis in ApoE&#x02212;/-mice via miR-let7 mediated infiltration and polarization of M2 macrophage. Biochem. Biophys. Res</article-title><source>Commun</source><year>2019</year><volume>510</volume><fpage>565</fpage><comment>-</comment><lpage>572</lpage></element-citation></ref><ref id="j_jtim-2023-0124_ref_103"><label>103</label><element-citation publication-type="journal"><name><surname>Cochain</surname><given-names>C</given-names></name><name><surname>Vafadarnejad</surname><given-names>E</given-names></name><name><surname>Arampatzi</surname><given-names>P</given-names></name><name><surname>Pelisek</surname><given-names>J</given-names></name><name><surname>Winkels</surname><given-names>H</given-names></name><name><surname>Ley</surname><given-names>K</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Single-cell RNA-seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis</article-title><source>Circ Res</source><year>2018</year><volume>122</volume><fpage>1661</fpage><comment>-</comment><lpage>1674</lpage><pub-id pub-id-type="pmid">29545365</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_104"><label>104</label><element-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Qin</surname><given-names>Z</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Exosomes as a mes-sager to regulate the crosstalk between macrophages and cardiomyocytes under hypoxia conditions</article-title><source>J Cell Mol Med</source><year>2022</year><volume>26</volume><fpage>1486</fpage><comment>-</comment><lpage>1500</lpage><pub-id pub-id-type="pmid">35088943</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_105"><label>105</label><element-citation publication-type="journal"><name><surname>Yancy</surname><given-names>CW</given-names></name><name><surname>Jessup</surname><given-names>M</given-names></name><name><surname>Bozkurt</surname><given-names>B</given-names></name><name><surname>Butler</surname><given-names>J</given-names></name><name><surname>Casey</surname><given-names>DE</given-names></name><name><surname>Drazner</surname><given-names>MH</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</article-title><source>J Am Coll Cardiol</source><year>2013</year><volume>62</volume><fpage>e147</fpage><comment>-</comment><lpage>e239</lpage><pub-id pub-id-type="pmid">23747642</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_106"><label>106</label><element-citation publication-type="journal"><name><surname>Nichols</surname><given-names>M</given-names></name><name><surname>Townsend</surname><given-names>N</given-names></name><name><surname>Scarborough</surname><given-names>P</given-names></name><name><surname>Rayner</surname><given-names>M</given-names></name><article-title>Cardiovascular disease in Europe 2014: epidemiological update</article-title><source>Eur Heart J</source><year>2014</year><volume>35</volume><fpage>2950</fpage><lpage>2959</lpage><pub-id pub-id-type="pmid">25139896</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_107"><label>107</label><element-citation publication-type="journal"><name><surname>Lejeune</surname><given-names>S</given-names></name><name><surname>Roy</surname><given-names>C</given-names></name><name><surname>Slimani</surname><given-names>A</given-names></name><name><surname>Pasquet</surname><given-names>A</given-names></name><name><surname>Vancraeynest</surname><given-names>D</given-names></name><name><surname>Vanoverschelde</surname><given-names>JL</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort</article-title><source>Cardiovasc Diabetol</source><year>2021</year><volume>20</volume><fpage>1</fpage><comment>-</comment><lpage>12</lpage><pub-id pub-id-type="pmid">33397395</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_108"><label>108</label><element-citation publication-type="journal"><name><surname>Paulus</surname><given-names>WJ</given-names></name><name><surname>Dal Canto</surname><given-names>E</given-names></name><article-title>Distinct myocardial targets for diabetes therapy in heart failure with preserved or reduced ejection fraction</article-title><source>JACC: Heart Failure</source><year>2018</year><volume>6</volume><fpage>1</fpage><comment>-</comment><lpage>7</lpage><pub-id pub-id-type="pmid">29284577</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_109"><label>109</label><element-citation publication-type="journal"><name><surname>Gaggin</surname><given-names>HK</given-names></name><name><surname>Januzzi Jr</surname><given-names>JL</given-names></name><article-title>Biomarkers and diagnostics in heart failure</article-title><source>Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease</source><year>2013</year><volume>1832</volume><fpage>2442</fpage><comment>-</comment><lpage>2450</lpage><pub-id pub-id-type="pmid">23313577</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_110"><label>110</label><element-citation publication-type="journal"><name><surname>Aurora</surname><given-names>P</given-names></name><name><surname>Edwards</surname><given-names>LB</given-names></name><name><surname>Kucheryavaya</surname><given-names>AY</given-names></name><name><surname>Christie</surname><given-names>JD</given-names></name><name><surname>Dobbels</surname><given-names>F</given-names></name><name><surname>Kirk</surname><given-names>R</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>The Registry of the International Society for Heart and Lung Transplantation: thirteenth official pediatric lung and heart-lung transplantation report&#x02014;2010</article-title><source>J Heart Lung Transplant</source><year>2010</year><volume>29</volume><fpage>1129</fpage><comment>-</comment><lpage>1141</lpage><pub-id pub-id-type="pmid">20870167</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_111"><label>111</label><element-citation publication-type="journal"><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Tao</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><article-title>Serum exosomal MiR-92b-5p as a potential biomarker for acute heart failure caused by dilated cardiomyopathy</article-title><source>Cell Physiol Biochem</source><year>2018</year><volume>46</volume><fpage>1939</fpage><comment>-</comment><lpage>1950</lpage><pub-id pub-id-type="pmid">29719295</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_112"><label>112</label><element-citation publication-type="journal"><name><surname>Hilfiker-Kleiner</surname><given-names>D</given-names></name><name><surname>Sliwa</surname><given-names>K</given-names></name><name><surname>Drexler</surname><given-names>H</given-names></name><article-title>Peripartum cardiomyopathy: recent insights in its pathophysiology</article-title><source>Trends Cardiovasc Med</source><year>2008</year><volume>18</volume><fpage>173</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">18790387</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_113"><label>113</label><element-citation publication-type="journal"><name><surname>Beg</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Saeed</surname><given-names>Z</given-names></name><name><surname>Devaraj</surname><given-names>S</given-names></name><name><surname>Masoor</surname><given-names>K</given-names></name><name><surname>Nakshatri</surname><given-names>H</given-names></name><article-title>Inflammation-associated microRNA changes in circulating exosomes of heart failure patients</article-title><source>BMC Res notes</source><year>2017</year><volume>10</volume><fpage>1</fpage><comment>-</comment><lpage>6</lpage><pub-id pub-id-type="pmid">28057050</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_114"><label>114</label><element-citation publication-type="journal"><name><surname>Halkein</surname><given-names>J</given-names></name><name><surname>Tabruyn</surname><given-names>SP</given-names></name><name><surname>Ricke-Hoch</surname><given-names>M</given-names></name><name><surname>Haghikia</surname><given-names>A</given-names></name><name><surname>Scherr</surname><given-names>M</given-names></name><name><surname>Caster-mans</surname><given-names>K</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>MicroRNA- 146a is a therapeutic target and biomarker for peripartum cardiomyopathy</article-title><source>J Clin Investig</source><year>2013</year><volume>123</volume><fpage>2143</fpage><comment>-</comment><lpage>2154</lpage><pub-id pub-id-type="pmid">23619365</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_115"><label>115</label><element-citation publication-type="journal"><name><surname>Zhou</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Momtazi&#x02010;Borojeni</surname><given-names>AA</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Circulating exosomal microRNAs as emerging non&#x02010;invasive clinical biomarkers in heart failure: mega bio&#x02010;roles of a nano bio&#x02010;particle</article-title><source>Iubmb Life</source><year>2020</year><volume>72</volume><fpage>2546</fpage><comment>-</comment><lpage>2562</lpage><pub-id pub-id-type="pmid">33053610</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_116"><label>116</label><element-citation publication-type="journal"><name><surname>Yang</surname><given-names>VK</given-names></name><name><surname>Loughran</surname><given-names>KA</given-names></name><name><surname>Meola</surname><given-names>DM</given-names></name><name><surname>Juhr</surname><given-names>CM</given-names></name><name><surname>Thane</surname><given-names>KE</given-names></name><name><surname>Davis</surname><given-names>AM</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Circulating exosome microRNA associated with heart failure secondary to myxomatous mitral valve disease in a naturally occurring canine model</article-title><source>J Extracell Vesicles</source><year>2017</year><volume>6</volume><fpage>1350088</fpage><pub-id pub-id-type="pmid">28804599</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_117"><label>117</label><element-citation publication-type="journal"><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Circular RNA-expression profiling reveals a potential role of Hsa_circ_0097435 in heart failure via sponging multiple microRNAs</article-title><source>Front Genet</source><year>2020</year><volume>11</volume><fpage>212</fpage><pub-id pub-id-type="pmid">32211036</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_118"><label>118</label><element-citation publication-type="journal"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Salvador</surname><given-names>AM</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Valkov</surname><given-names>N</given-names></name><name><surname>Ziegler</surname><given-names>O</given-names></name><name><surname>Yeri</surname><given-names>A</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Mir-30d regulates cardiac remodeling by intracellular and paracrine signaling</article-title><source>Circ Res</source><year>2021</year><volume>128</volume><fpage>e1</fpage><comment>-</comment><lpage>e23</lpage><pub-id pub-id-type="pmid">33092465</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_119"><label>119</label><element-citation publication-type="journal"><name><surname>Vegter</surname><given-names>EL</given-names></name><name><surname>van der Meer</surname><given-names>P</given-names></name><name><surname>de Windt</surname><given-names>LJ</given-names></name><name><surname>Pinto</surname><given-names>YM</given-names></name><name><surname>Voors</surname><given-names>AA</given-names></name><article-title>MicroRNAs in heart failure: from biomarker to target for therapy</article-title><source>Eur J Heart Fail</source><year>2016</year><volume>18</volume><fpage>457</fpage><comment>-</comment><lpage>468</lpage><pub-id pub-id-type="pmid">26869172</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_120"><label>120</label><element-citation publication-type="journal"><name><surname>Potus</surname><given-names>F</given-names></name><name><surname>Ruffenach</surname><given-names>G</given-names></name><name><surname>Dahou</surname><given-names>A</given-names></name><name><surname>Thebault</surname><given-names>C</given-names></name><name><surname>Breuils-Bonnet</surname><given-names>S</given-names></name><name><surname>Tremblay</surname><given-names>&#x000c8;</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Downregulation of microRNA- 126 contributes to the failing right ventricle in pulmonary arterial hypertension</article-title><source>Circulation</source><year>2015</year><volume>132</volume><fpage>932</fpage><lpage>943</lpage><pub-id pub-id-type="pmid">26162916</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_121"><label>121</label><element-citation publication-type="journal"><name><surname>Huang</surname><given-names>JP</given-names></name><name><surname>Chang</surname><given-names>CC</given-names></name><name><surname>Kuo</surname><given-names>CY</given-names></name><name><surname>Huang</surname><given-names>KJ</given-names></name><name><surname>Sokal</surname><given-names>EM</given-names></name><name><surname>Chen</surname><given-names>KH</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Exosomal microRNAs miR-30d-5p and miR-126a-5p are associated with heart failure with preserved ejection fraction in STZ-induced type 1 diabetic rats</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><fpage>7514</fpage><pub-id pub-id-type="pmid">35886860</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_122"><label>122</label><element-citation publication-type="journal"><name><surname>Xiao</surname><given-names>YC</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>WY</given-names></name><name><surname>Tan</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>YK</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>The peripheral circulating exosomal microRNAs related to central inflammation in chronic heart failure</article-title><source>J Cardiovasc Transl Res</source><year>2022</year><fpage>1</fpage><comment>-</comment><lpage>14</lpage><pub-id pub-id-type="pmid">35137336</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_123"><label>123</label><element-citation publication-type="journal"><name><surname>Yan</surname><given-names>F</given-names></name><name><surname>Cui</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><article-title>Mesenchymal stem cell-derived exosome-loaded microRNA-129-5p inhibits TRAF3 expression to alleviate apoptosis and oxidative stress in heart failure. Cardiovasc</article-title><source>Toxicol</source><year>2022</year><fpage>1</fpage><comment>-</comment><lpage>15</lpage></element-citation></ref><ref id="j_jtim-2023-0124_ref_124"><label>124</label><element-citation publication-type="journal"><name><surname>Wang</surname><given-names>Q-G</given-names></name><name><surname>Cheng</surname><given-names>BCY</given-names></name><name><surname>He</surname><given-names>Y-Z</given-names></name><name><surname>Li</surname><given-names>L-J</given-names></name><name><surname>Ling</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>G</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>miR&#x02011;320a in serum exosomes promotes myocardial fibroblast proliferation via regulating the PIK3CA/Akt/mTOR signaling pathway in HEH2 cells</article-title><source>Exp Ther Med</source><year>2021</year><volume>22</volume><fpage>1</fpage><comment>-</comment><lpage>14</lpage></element-citation></ref><ref id="j_jtim-2023-0124_ref_125"><label>125</label><element-citation publication-type="journal"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><article-title>Exosomal micro-RNA&#x02010;1246 from human umbilical cord mesenchymal stem cells potentiates myocardial angiogenesis in chronic heart failure</article-title><source>Cell biology international</source><year>2021</year><volume>45</volume><fpage>2211</fpage><comment>-</comment><lpage>2225</lpage><pub-id pub-id-type="pmid">34270841</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_126"><label>126</label><element-citation publication-type="journal"><name><surname>Rubler</surname><given-names>S</given-names></name><name><surname>Dlugash</surname><given-names>J</given-names></name><name><surname>Yuceoglu</surname><given-names>YZ</given-names></name><name><surname>Kumral</surname><given-names>T</given-names></name><name><surname>Branwood</surname><given-names>AW</given-names></name><name><surname>Grishman</surname><given-names>A</given-names></name><article-title>New type of cardiomyopathy associated with diabetic glomerulosclerosis</article-title><source>Am J Cardiol</source><year>1972</year><volume>30</volume><fpage>595</fpage><comment>-</comment><lpage>602</lpage><pub-id pub-id-type="pmid">4263660</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_127"><label>127</label><element-citation publication-type="journal"><name><surname>Cheng</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>E</given-names></name><name><surname>Zeng</surname><given-names>Q</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Circulating myocardial microRNAs from infarcted hearts are carried in exosomes and mobilise bone marrow progenitor cells</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><fpage>1</fpage><comment>-</comment><lpage>9</lpage><pub-id pub-id-type="pmid">30602773</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_128"><label>128</label><element-citation publication-type="journal"><name><surname>Copier</surname><given-names>CU</given-names></name><name><surname>Le&#x000f3;n</surname><given-names>L</given-names></name><name><surname>Fern&#x000e1;ndez</surname><given-names>M</given-names></name><name><surname>Contador</surname><given-names>D</given-names></name><name><surname>Calligaris</surname><given-names>SD</given-names></name><article-title>Circulating miR- 19b and miR- 181b are potential biomarkers for diabetic cardiomyopathy</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>1</fpage><comment>-</comment><lpage>11</lpage><pub-id pub-id-type="pmid">28127051</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_129"><label>129</label><element-citation publication-type="journal"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Millard</surname><given-names>RW</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Cardiomyocytes mediate anti-angiogenesis in type 2 diabetic rats through the exosomal transfer of miR-320 into endothelial cells</article-title><source>J Mol Cell Cardiol</source><year>2014</year><volume>74</volume><fpage>139</fpage><comment>-</comment><lpage>150</lpage><pub-id pub-id-type="pmid">24825548</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_130"><label>130</label><element-citation publication-type="journal"><name><surname>Chaturvedi</surname><given-names>P</given-names></name><name><surname>Kalani</surname><given-names>A</given-names></name><name><surname>Medina</surname><given-names>I</given-names></name><name><surname>Familtseva</surname><given-names>A</given-names></name><name><surname>Tyagi</surname><given-names>SC</given-names></name><article-title>Cardiosome mediated regulation of MMP 9 in diabetic heart: Role of mir29b and mir455 in exercise</article-title><source>J Cell. Mol Med</source><year>2015</year><volume>19</volume><fpage>2153</fpage><comment>-</comment><lpage>2161</lpage><pub-id pub-id-type="pmid">25824442</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_131"><label>131</label><element-citation publication-type="journal"><name><surname>Semple</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Bhandari</surname><given-names>S</given-names></name><name><surname>Seymour</surname><given-names>AML</given-names></name><article-title>Uremic cardiomyopathy and insulin resistance: a critical role for akt?</article-title><source>J Am Soc Nephrol</source><year>2011</year><volume>22</volume><fpage>207</fpage><comment>-</comment><lpage>215</lpage><pub-id pub-id-type="pmid">20634295</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_132"><label>132</label><element-citation publication-type="journal"><name><surname>Wang</surname><given-names>XH</given-names></name><name><surname>Mitch</surname><given-names>WE</given-names></name><article-title>Mechanisms of muscle wasting in chronic kidney disease</article-title><source>Nat Rev Nephrol</source><year>2014</year><volume>10</volume><fpage>504</fpage><comment>-</comment><lpage>516</lpage><pub-id pub-id-type="pmid">24981816</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_133"><label>133</label><element-citation publication-type="journal"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Klein</surname><given-names>JD</given-names></name><name><surname>Tan</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Z-M</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>miR-26a limits muscle wasting and cardiac fibrosis through exosome-mediated microRNA transfer in chronic kidney disease</article-title><source>Theranostics</source><year>2019</year><volume>9</volume><fpage>1864</fpage><pub-id pub-id-type="pmid">31037144</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_134"><label>134</label><element-citation publication-type="journal"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Z-M</given-names></name><name><surname>Ji</surname><given-names>J-L</given-names></name><name><surname>Gan</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Shi</surname><given-names>H-J</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Macrophage-derived exosomal Mir-155 regulating cardiomyocyte pyroptosis and hypertrophy in uremic cardiomyopathy</article-title><source>Basic to Translational Science</source><year>2020</year><volume>5</volume><fpage>148</fpage><comment>-</comment><lpage>166</lpage><pub-id pub-id-type="pmid">32140622</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_135"><label>135</label><element-citation publication-type="journal"><name><surname>Wild</surname><given-names>S</given-names></name><name><surname>Roglic</surname><given-names>G</given-names></name><name><surname>Green</surname><given-names>A</given-names></name><name><surname>Sicree</surname><given-names>R</given-names></name><name><surname>King</surname><given-names>H</given-names></name><article-title>Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.</article-title><source>Diabetes care</source><year>2004</year><volume>27</volume><fpage>1047</fpage><comment>-</comment><lpage>1053</lpage><pub-id pub-id-type="pmid">15111519</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_136"><label>136</label><element-citation publication-type="journal"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><article-title>Exosomal microRNA-122 mediates obesity-related cardiomyopathy through suppressing mitochondrial ADP-ribosylation factor-like 2</article-title><source>Clin Sci</source><year>2019</year><volume>133</volume><fpage>1871</fpage><comment>-</comment><lpage>1881</lpage></element-citation></ref><ref id="j_jtim-2023-0124_ref_137"><label>137</label><element-citation publication-type="journal"><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Exosomal microRNA-29a mediates cardiac dysfunction and mitochondrial inactivity in obesity-related cardiomyopathy</article-title><source>Endocrine</source><year>2019</year><volume>63</volume><fpage>480</fpage><comment>-</comment><lpage>488</lpage><pub-id pub-id-type="pmid">30264370</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_138"><label>138</label><element-citation publication-type="journal"><name><surname>Ibrahim</surname><given-names>AG-E</given-names></name><name><surname>Cheng</surname><given-names>K</given-names></name><name><surname>Marb&#x000e1;n</surname><given-names>E</given-names></name><article-title>Exosomes as critical agents of cardiac regeneration triggered by cell therapy</article-title><source>Stem Cell Rep</source><year>2014</year><volume>2</volume><fpage>606</fpage><comment>-</comment><lpage>619</lpage></element-citation></ref><ref id="j_jtim-2023-0124_ref_139"><label>139</label><element-citation publication-type="journal"><name><surname>Vandergriff</surname><given-names>AC</given-names></name><name><surname>de Andrade</surname><given-names>JBM</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Hensley</surname><given-names>MT</given-names></name><name><surname>Piedrahita</surname><given-names>JA</given-names></name><name><surname>Caranasos</surname><given-names>TG</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Intravenous cardiac stem cell-derived exosomes ameliorate cardiac dysfunction in doxorubicin induced dilated cardiomyopathy</article-title><source>Stem Cells Int</source><year>2015</year><comment>2015</comment></element-citation></ref><ref id="j_jtim-2023-0124_ref_140"><label>140</label><element-citation publication-type="journal"><name><surname>Shaihov-Teper</surname><given-names>O</given-names></name><name><surname>Ram</surname><given-names>E</given-names></name><name><surname>Ballan</surname><given-names>N</given-names></name><name><surname>Brzezinski</surname><given-names>RY</given-names></name><name><surname>Naftali-Shani</surname><given-names>N</given-names></name><name><surname>Masoud</surname><given-names>R</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Extracellular vesicles from epicardial fat facilitate atrial fibrillation</article-title><source>Circulation</source><year>2021</year><volume>143</volume><fpage>2475</fpage><comment>-</comment><lpage>2493</lpage><pub-id pub-id-type="pmid">33793321</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_141"><label>141</label><element-citation publication-type="journal"><name><surname>Krijthe</surname><given-names>BP</given-names></name><name><surname>Kunst</surname><given-names>A</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name><name><surname>Franco</surname><given-names>OH</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060.</article-title><source>Eur Heart J</source><year>2013</year><volume>34</volume><fpage>2746</fpage><comment>-</comment><lpage>2751</lpage><pub-id pub-id-type="pmid">23900699</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_142"><label>142</label><element-citation publication-type="journal"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Min</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Yin</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Differentially expressed miRNAs in circulating exosomes between atrial fibrillation and sinus rhythm</article-title><source>J Thorac. Dis</source><year>2019</year><volume>11</volume><fpage>4337</fpage><pub-id pub-id-type="pmid">31737319</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_143"><label>143</label><element-citation publication-type="journal"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Shu</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>C-E</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>F</given-names></name><article-title>Identification of microRNAs enriched in exosomes in human pericardial fluid of patients with atrial fibrillation based on bioinformatic analysis</article-title><source>J Thorac Dis</source><year>2020</year><volume>12</volume><fpage>5617</fpage><pub-id pub-id-type="pmid">33209394</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_144"><label>144</label><element-citation publication-type="journal"><name><surname>Qi</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Ji</surname><given-names>N</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>The pluripotent role of exosomes in mediating non-coding RNA in ventricular remodeling after myocardial infarction</article-title><source>Life Sci</source><year>2020</year><volume>254</volume><fpage>117761</fpage><pub-id pub-id-type="pmid">32413403</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_145"><label>145</label><element-citation publication-type="journal"><name><surname>Gray</surname><given-names>WD</given-names></name><name><surname>French</surname><given-names>KM</given-names></name><name><surname>Ghosh-Choudhary</surname><given-names>S</given-names></name><name><surname>Maxwell</surname><given-names>JT</given-names></name><name><surname>Brown</surname><given-names>ME</given-names></name><name><surname>Platt</surname><given-names>MO</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Identification of therapeutic covariant microRNA clusters in hypoxia-treated cardiac progenitor cell exosomes using systems biology</article-title><source>Circ Res</source><year>2015</year><volume>116</volume><fpage>255</fpage><comment>-</comment><lpage>263</lpage><pub-id pub-id-type="pmid">25344555</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_146"><label>146</label><element-citation publication-type="journal"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Mao</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><article-title>Exosomal miR-320d derived from adipose tissue-derived MSCs inhibits apoptosis in cardiomyocytes with atrial fibrillation (AF)</article-title><source>Artif Cells Nanomed Biotechnol</source><year>2019</year><volume>47</volume><fpage>3976</fpage><lpage>3984</lpage><pub-id pub-id-type="pmid">31591913</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_147"><label>147</label><element-citation publication-type="journal"><name><surname>Tung</surname><given-names>SL</given-names></name><name><surname>Boardman</surname><given-names>DA</given-names></name><name><surname>Sen</surname><given-names>M</given-names></name><name><surname>Letizia</surname><given-names>M</given-names></name><name><surname>Peng</surname><given-names>Q</given-names></name><name><surname>Cianci</surname><given-names>N</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Regulatory T cell-derived extracellular vesicles modify dendritic cell function</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><fpage>1</fpage><comment>-</comment><lpage>12</lpage><pub-id pub-id-type="pmid">29311619</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_148"><label>148</label><element-citation publication-type="journal"><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Chu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Exosomes from Bone Marrow Mesenchymal Stem Cells with Overexpressed Nrf2 Inhibit Cardiac Fibrosis in Rats with Atrial Fibrillation</article-title><source>Cardiovasc Ther</source><year>2022</year><comment>2022</comment></element-citation></ref><ref id="j_jtim-2023-0124_ref_149"><label>149</label><element-citation publication-type="journal"><name><surname>Lindenfeld</surname><given-names>J</given-names></name><name><surname>Albert</surname><given-names>NM</given-names></name><name><surname>Boehmer</surname><given-names>JP</given-names></name><name><surname>Collins</surname><given-names>SP</given-names></name><name><surname>Ezekowitz</surname><given-names>JA</given-names></name><name><surname>Givertz</surname><given-names>MM</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>HFSA 2010 comprehensive heart failure practice guideline.</article-title><source>J Card Fail</source><year>2010</year><volume>16</volume><fpage>e1</fpage><comment>-</comment><lpage>194</lpage><pub-id pub-id-type="pmid">20610207</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_150"><label>150</label><element-citation publication-type="journal"><name><surname>Kondo</surname><given-names>T</given-names></name><name><surname>Okumura</surname><given-names>T</given-names></name><name><surname>Shibata</surname><given-names>N</given-names></name><name><surname>Imaizumi</surname><given-names>T</given-names></name><name><surname>Dohi</surname><given-names>K</given-names></name><name><surname>Izawa</surname><given-names>H</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Differences in prognosis and cardiac function according to required percutaneous mechanical circulatory support and histological findings in patients with fulminant myocarditis: Insights from the CHANGE PUMP 2 study</article-title><source>J Am Heart Assoc</source><year>2022</year><volume>11</volume><fpage>e023719</fpage><pub-id pub-id-type="pmid">35132864</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_151"><label>151</label><element-citation publication-type="journal"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Ma</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Altered plasma exosome miRNAs and novel potential biomarkers in pediatric fulminant myocarditis</article-title><source>Genomics</source><year>2023</year><fpage>110622</fpage><pub-id pub-id-type="pmid">37062366</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_152"><label>152</label><element-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Lv</surname><given-names>K</given-names></name><article-title>Serum exosome microRNA panel as a noninvasive biomarker for molecular diagnosis of fulminant myocarditis</article-title><source>Mol Ther Methods Clin Dev</source><year>2021</year><volume>20</volume><fpage>142</fpage><comment>-</comment><lpage>151</lpage><pub-id pub-id-type="pmid">33473354</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_153"><label>153</label><element-citation publication-type="journal"><name><surname>Pollack</surname><given-names>A</given-names></name><name><surname>Kontorovich</surname><given-names>AR</given-names></name><name><surname>Fuster</surname><given-names>V</given-names></name><name><surname>Dec</surname><given-names>GW</given-names></name><article-title>Viral myocarditis&#x02014;diagnosis, treatment options, and current controversies</article-title><source>Nat Rev Cardiol</source><year>2015</year><volume>12</volume><fpage>670</fpage><comment>-</comment><lpage>680</lpage><pub-id pub-id-type="pmid">26194549</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_154"><label>154</label><element-citation publication-type="journal"><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Xiong</surname><given-names>S</given-names></name><name><surname>Yue</surname><given-names>Y</given-names></name><article-title>Exosome-based delivery of VP1 protein conferred enhanced resistance of mice to CVB3-induced viral myocarditis</article-title><source>Virology</source><year>2023</year></element-citation></ref><ref id="j_jtim-2023-0124_ref_155"><label>155</label><element-citation publication-type="journal"><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Lian</surname><given-names>H</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Exosomes derived from umbilical cord mesenchymal stem cells alleviate viral myocarditis through activating AMPK/mTOR&#x02010;mediated autophagy flux pathway</article-title><source>J Cell Mol Med</source><year>2020</year><volume>24</volume><fpage>7515</fpage><comment>-</comment><lpage>7530</lpage><pub-id pub-id-type="pmid">32424968</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_156"><label>156</label><element-citation publication-type="journal"><name><surname>Xitong</surname><given-names>D</given-names></name><name><surname>Xiaorong</surname><given-names>Z</given-names></name><article-title>Targeted therapeutic delivery using engineered exosomes and its applications in cardiovascular diseases</article-title><source>Gene</source><year>2016</year><volume>575</volume><fpage>377</fpage><comment>-</comment><lpage>384</lpage><pub-id pub-id-type="pmid">26341056</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_157"><label>157</label><element-citation publication-type="journal"><name><surname>Zimmer</surname><given-names>L</given-names></name><name><surname>Livingstone</surname><given-names>E</given-names></name><name><surname>Hassel</surname><given-names>JC</given-names></name><name><surname>Fluck</surname><given-names>M</given-names></name><name><surname>Eigentler</surname><given-names>T</given-names></name><name><surname>Loquai</surname><given-names>C</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial</article-title><source>Lancet (London, England)</source><year>2020</year><volume>395</volume><fpage>1558</fpage><comment>-</comment><lpage>1568</lpage><pub-id pub-id-type="pmid">32416781</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_158"><label>158</label><element-citation publication-type="journal"><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Du</surname><given-names>Z</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Stem cell-derived exosome in cardiovascular diseases: macro roles of micro particles</article-title><source>Front Pharmacol</source><year>2018</year><volume>9</volume><fpage>547</fpage><pub-id pub-id-type="pmid">29904347</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_159"><label>159</label><element-citation publication-type="journal"><name><surname>Xue</surname><given-names>R</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>B</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>P</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Role of exosomal miRNAs in heart failure</article-title><source>Front Cardiovasc Med</source><year>2020</year><volume>7</volume><fpage>592412</fpage><pub-id pub-id-type="pmid">33392270</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0124_ref_160"><label>160</label><element-citation publication-type="journal"><name><surname>Tang</surname><given-names>Y-T</given-names></name><name><surname>Huang</surname><given-names>Y-Y</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Qin</surname><given-names>S-H</given-names></name><name><surname>Xu</surname><given-names>X-P</given-names></name><name><surname>An</surname><given-names>T-X</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Comparison of isolation methods of exosomes and exosomal RNA from cell culture medium and serum</article-title><source>Int J Mol Med</source><year>2017</year><volume>40</volume><fpage>834</fpage><comment>-</comment><lpage>844</lpage><pub-id pub-id-type="pmid">28737826</pub-id>
</element-citation></ref></ref-list></back></article>
